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Aberrant splicing of pre-mRNA is common in cancer cells, and may create cancer-
specific transcript variants. These abnormal transcripts, as well as their derived 
protein products, may have the potential to function as diagnostic and prognostic 
biomarkers, and even as therapeutic drug targets. Current biomarkers do not satisfy 
the requirements of sensitivity and specificity; accordingly, the search for novel 
transcript structures in cancer is promising. 
In the present thesis, the overall aim was to discover novel cancer-specific transcript 
variants, as well as skewed ratios between pre-existing transcripts, in colorectal and 
testicular cancers. To reach that goal, candidate differentially expressed exons 
between malignant and non-malignant samples from exon-level microarray data were 
investigated. As the results from such microarrays are not intuitive in identifying the 
transcript structures, and numerous false positives arise, it is absolutely essential to 
validate and explore the exon microarray results by another method. 
We used RT-PCR based approaches on the 30 apparently most promising candidate 
genes identified by exon microarrays to validate possible differential exon inclusion, 
as well as to reveal the structure of the candidate cancer-specific transcript variants. 
Six of the 30 candidate genes (SLC39A14, DDX17, SF1, ZNF195, PMF1, and 
DNMT3B) were successfully validated as having differences in transcript variants in 
the same samples as analysed by the exon microarray analyses. These transcripts 
were further investigated in extended sample series. Transcript variants of 
SLC39A14, DDX17 and SF1, originally identified from the colorectal cancer dataset, 
were further investigated in 105 colorectal cancers, eight normal tissues, and in six 
colon cancer cell lines. Transcript variants of ZNF195, PMF1 and DNMT3B, 
originally identified from the testicular cancer dataset, were further investigated in 25 
testicular germ cell tumours, as well as in six pre-malignant intratubular germ cell 
neoplasias, and five normal testicular parenchyma tissue samples, in addition to five 
embryonal carcinoma cell lines and two embryonic stem cell lines. 
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Differential ratios between pre-existing transcripts were found for all six genes. 
ZNF195 was identified as a particularly highly expressed gene in pluripotent samples 
(both embryonal carcinoma and embryonic stem cells), and with a malignancy-
specific ratio between the transcript variants. Regarding DDX17 and SF1, the 
colorectal cancer tissue samples revealed a higher proportion of the candidate cancer-
specific transcript as compared to the normal tissue samples. However, the most 
promising candidate biomarker found in this study was SLC39A14, which appeared 
to have two mutually exclusive exons with differential inclusion in malignant and 
normal tissues from colon and rectum. Real-time RT-PCR revealed that 78 of the 105 
(74 %) colorectal cancer tissue samples exclusively expressed the cancer-specific 
exon, whereas six of the eight normal tissue samples exclusively expressed the other 
transcript variant. Including the remaining samples, only two of the 105 colorectal 
cancer tissue samples showed an expression ratio between the two different 
transcripts that mixed with the normal tissue samples. 
Altogether, we have identified novel transcript variants that may serve as improved 
biomarkers in colorectal (SLC39A14) and testicular cancer (ZNF195). 
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3'SS 3' splice site 
3'UTR 3' untranslated region 
5'SS 5' splice site 
5'UTR 5' untranslated region 
bp Base pairs 
APS Alternative polyadenylation site 
BPS Branch point sequence 
cDNA Complementary DNA 
CIMP CpG island methylator phenotype  
CIN Chromosome instable 
CML Chronic myelogenous leukaemia 
CRC Colorectal cancer 
Ct Cycle threshold 
ddNTP Dideoxyribonucleotide triphosphate 
DNA Deoxyribonucleic acid 
dNTP Deoxyribonucleotide triphosphate 
EC Embryonal carcinoma 
EDTA Ethylenediaminetetraacetic acid 
ES Embryonic stem cell 
ESE Exonic splicing enhancer 
ESS Exonic splicing silencer 
EST Expressed sequence tag 
FAP Familial adenomatous polyposis 
FDR False discovery rate 
FIRMA Finding isoforms using robust multichip analysis 
Hi-Di formamide Highly deionised formamide 
HNPCC Hereditary non-polyposis colorectal cancer 
hnRNP Heterogenous nuclear ribonucleoprotein 
i(12p) Isochromosome 12p 
ICM Inner cell mass 
IGCN Intratubular germ cell neoplasia 
ISE Intronic splicing enhancer 
ISS Intronic splicing silencer 
MGB Minor groove binder 
miRNA Micro ribonucleic acid 
MMR Mismatch repair 
mRNA Messenger RNA 
MSI Microsatellite instable 
NMD Nonsense-mediated mRNA decay 
PCR Polymerase chain reaction 
PGC Primordial germ cell 
PPT Polypyrimidine tract 
pre-mRNA Precursor messenger ribonucleic acid 
PSR Probe selection region 
RACE Rapid amplification of cDNA ends 
RNA Ribonucleic acid 
RT-PCR Reverse transcriptase polymerase chain reaction 
siRNA Short interfering RNA 
snRNA Small nuclear ribonucleic acid 
snRNP Small nuclear ribonucleic protein 
  8
SR protein Serine/arginine-rich protein 
TAE buffer Tris-acetate EDTA buffer 
TGCT Testicular germ cell tumour 
Tm Melting temperature 
TSS Transcription start site 




ABL c-abl oncogene 1 
APC Adenomatous polyposis coli 
BCL-X BCL2-like 1 
BCR1 Breakpoint cluster region 
BRCA1 Breast cancer 1, early onset 
DDX17 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 
DNMT3B DNA (cytosine-5)-methyltransferase 3β 
GCNT3 Glucosaminyl (N-acetyl) transferase 3, mucin type 
ING4 Inhibitor of growth family, member 4 
LEF1 Lymphoid enhancer-binding factor 1 
MLH1 mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) 
MSH2 mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) 
PMF1 Polyamine-modulated factor 1 
SF1 Splicing factor 1 
SLC39A14 Solute carrier family 39 (zinc transporter), member 14  




1.1 A brief introduction to cancer 
Malignant tumours are generally considered to arise from a single cell of origin [1], 
but there is evidence for the existence of polyclonal tumours as well [2]. 
Tumourigenesis is a multistep process resulting from acquired genetic and epigenetic 
variability among the cancer cells, leading to the sequential selection of more 
aggressive sublines [1,3]. The following phenotypic changes have been referred to as 
“the hallmarks of cancer”: self-sufficiency in growth signals, insensitivity to growth-
inhibitory signals, evasion of apoptosis, limitless replicative potential, sustained 
angiogenesis, and tissue invasion and metastasis [4]. Genomic instability [5] and the 
ability to escape the host immune system [6] are also regarded as acquired 
capabilities of cancer. 
As early as in 1914, the German pathologist Theodor Boveri published a reflective 
monograph on the connection between chromosomal anomalies and tumour 
development [7]. Almost half a century passed before Boveri’s idea received some 
validation. In 1960, two cytologists working in Philadelphia noted that an abnormal, 
unusually small chromosome was characteristically present in chronic myelogenous 
leukaemia (CML) cells [8]. The origin of this so-called Philadelphia chromosome 
was not solved until 1973, when Janet D. Rowley demonstrated that a reciprocal 
translocation between chromosomes 9 and 22 was responsible for creating the minute 
chromosome [9]. 
Today we know that this particular translocation is present in approximately 95 % of 
all CML cases [10], and that it results in the fusion of the BCR1 gene and the proto-
oncogene ABL. The hybrid BCR1-ABL oncoprotein product functions as a 
constitutively activated tyrosine kinase [11]. 
Introduction 
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Proto-oncogenes encode proteins which functions often are to control cell 
proliferation, apoptosis, or both, and as intimated above, cellular proto-oncogenes can 
be activated by structural alterations resulting from gene fusions. Mutations affecting 
crucial residues, and overexpression caused by e. g. genomic amplifications [12] or 
juxtaposition to enhancer elements [13], represent other ways to activate oncogenes. 
Inactivations of tumour suppressor genes, in addition to alterations of DNA repair 
genes (the caretakers), also contribute to growth and proliferation advantages and 
stepwise tumour formation. Tumour suppressor genes encode proteins whose normal 
function is to reduce the likelihood of tumour formation, and usually both alleles 
need to be inactivated to provide tumourigenic effects. The loss of tumour suppressor 
gene function can occur either through genetic mutation or epigenetic silencing of 
genes via promoter methylation. Despite that the genome in most cancer cells is 
hypomethylated at repetitive DNA sequences at the global level, local 
hypermethylation of CpG islands1 in the promoter regions of tumour suppressor 
genes is a major event in the origin of many cancers [3]. 
The first drafts of the human genome was published in 2001 [14,15], and the current 
estimate of human genes is ranging from 20 000 to 25 000 [16]. The variation at the 
RNA and protein levels accounts for the high diversity and complexity of higher 
eukaryotes. Instability at the transcriptome and proteome levels adds further 
complexity to cancer cells. 
1.2 Transcript variation in cancer 
One mechanism that accounts for the greater complexity and protein diversity of 
higher eukaryotes is alternative splicing of the RNA molecules. Through alternative 
splicing, a single gene is able to generate several transcript variants from one type of 
precursor messenger RNA (pre-mRNA), which may lead to the production of 
                                               
1 CpG island – region of the genome with significantly higher than average content of the CpG dinucleotide. 
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different protein isoforms. Alteration of the normal process of alternative splicing is 
frequent in cancer cells, and may result in the production of previously absent 
mRNAs or in the modification of the ratio between pre-existing mRNAs. Both these 
scenarios may be used as diagnostic and prognostic biomarkers, although the most 
promising biomarkers are those that are entirely cancer-specific. Furthermore, 
aberrant splice products with functional implications may be exploited in targeted 
therapeutics. 
Most studies of cancer transcriptomes have been purely quantitative in nature, and do 
not take into account the qualitative variation of transcript variants. In the following, 
the contribution of alternative splicing and alternative use of promoters and 
polyadenylation sites to transcriptome diversity will be explained – both in general 
and in relation to cancer. Fusion transcripts2 are also common in cancer [17], but will 
not be further described in this thesis. Finally, methods used in the analysis of 
transcriptomes will be discussed. 
1.2.1 Alternative splicing  
The median number of exons in a human protein-coding gene is seven, while the 
median internal exon length is 122 bp [14]. The exons are interrupted by usually 
much longer non-coding introns. Genes are transcribed into pre-mRNAs, containing 
exons as well as introns, and in the process of splicing the introns are removed from 
the transcripts and the adjacent exons are ligated. 
Splicing of metazoan pre-mRNAs involves two transesterification reactions and 
functional groups from three poorly conserved reactive regions in the primary 
transcript; the 5’ and 3’ splice sites (5’SS and 3’SS, respectively), and the branch 
point sequence (BPS) (Figure 1) [as thoroughly reviewed in reference 18]. 
                                               




Figure 1. Pre-mRNA reactive regions. The locations of the three pre-mRNA reactive 
regions, the 5’ and 3’ splice sites (5’SS and 3’SS, respectively) and the branch point 
sequence (BPS), are indicated. The polypyrimidine tract (PPT) is located between the BPS 
and the 3’SS. The BPS, PPT and 3’SS sequence elements are all situated in the 3’ end of 
the intron. 
First, the phosphodiester bond at the 5’SS is attacked by the 2’-hydroxyl of an 
adenosine of the intronic BPS, which generates a free 5’ exon and an intron lariat-3’ 
exon. Then, the 3’-hydroxyl of the 5’ exon attacks the phosphodiester bond at the 
3’SS, resulting in exon ligation and excision of the lariat intron. The folding of pre-
mRNA introns in a manner consistent with splicing is dependent on several trans-
acting factors that comprise the spliceosome [18]. 
The splicing reaction is carried out in the nucleus by the spliceosomal complex 
consisting of five small nuclear ribonucleoproteins (snRNP), U1, U2, U4/U6, and U5, 
and more than 100 other proteins [19]. The spliceosome recognises the 5’SS and the 
3’SS, in addition to the BPS and the polypyrimidine tract (PPT), and catalyses the 
cut-and-paste reactions. Assembly of the spliceosome on the pre-mRNA begins with 
the binding of U1 snRNP to the 5’SS. The earliest assembly phase also involves 
binding of the interacting proteins SF1/BBP and U2 auxiliary factor (U2AF) to the 
BPS, and the PPT and 3’SS sequences, respectively. Together, these molecular 
interactions yield the spliceosomal E complex. Subsequently, the U2 snRNP binds 
the BPS, leading to the displacement of SF1/BBP and the formation of the A 
complex. Then, the preassembled tri-snRNP consisting of U4/U6 and U5 snRNPs are 
recruited to the transcript, resulting in the formation of the B complex. During the 
activation of the spliceosome the complex goes through extensive structural and 
compositional rearrangements, including U1 and U4 destabilisation or release, 
resulting in the formation of the catalytically active spliceosome [18]. 
Alternative splicing can be defined as the joining of different 5’ and 3’ splice sites to 
produce distinct mRNAs [20], and has been estimated to occur in 86 % of all human 
genes [21]. Recognition and selection of splice sites in higher eukaryotes is 
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influenced by pre-mRNA regulatory sequences known as intronic and exonic splicing 
enhancers and silencers (abbreviated ISE, ESE, ISS, and ESS). These cis-acting 
elements have positive (ISE and ESE) or negative (ISS and ESS) influence on splice-
site usage, and mediate their effects mainly by binding trans-acting regulatory factors 
[18] (Figure 2). 
 
Figure 2. Cis-acting elements involved in constitutive and alternative splicing. Green 
arrows indicate the positive activity of splicing enhancers on the selection of adjacent splice 
sites in the alternative and constitutive exons. Red arrows with flat heads signify the 
negative activity of splicing silencers in cryptic exons and intronic regions proximal to cryptic 
splice sites, as well as in the alternative exon [modified from reference 22]. 
The trans-acting factors recruit the snRNP subunits of the splicing machinery to the 
adjacent splice site or, in the case of negative regulators, prevent their association. 
ESEs are often bound by proteins of the serine-arginine-rich (SR) protein family, 
whereas ESSs are typically bound by heterogeneous nuclear RNPs (hnRNPs). 
Eventually, it is the sum of multiple factors that decides whether a particular site is 
recognised by the spliceosome for inclusion of the adjacent exon in the mature 
mRNA [18]. 
The regulation of alternative splicing depends not only on the interaction between 
cis-acting elements and trans-acting factors, but also on the rate and pausing of 
transcriptional elongation. This can be explained by the fact that in the absence of 
internal stops, or during fast elongation, the 3’SSs of both an alternative cassette exon 
and a downstream constitutive exon might be presented simultaneously to the 
splicing machinery. Usually, the 3’SS of the alternative exon is weaker than the 3’SS 
of the constitutive exon, resulting in exon skipping. In the opposite, when the RNA 
polymerase II halts, or moves slowly, the weak 3’SS of the alternative exon is 
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available to the spliceosome on its own, leading to inclusion of the alternative exon 
[23]. 
The most common type of alternative splicing involves cassette-type alternative 
exons, which are either skipped or included in the mature mRNA. Alternative 
selection of 5’ and 3’ splice sites within exon sequences are also frequent, resulting in 
varying inclusion of sequence from a particular exon. Other types of alternative 
splicing events include intron retention and exons that are spliced in a mutually 
exclusive fashion. Mutually exclusive exons are never expressed in the same mature 
mRNA [22] (Figure 3). 
 
Figure 3. Different alternative splicing events. Blue and orange boxes indicate 
constitutive and alternative exons, respectively. These colour codes are recurrent in several 
figures in this thesis. 
Up to one-third of human alternative splicing events create a premature stop codon, 
that generally results in the degradation of the transcript by nonsense-mediated 
mRNA decay3 (NMD) [25]. However, some alternative mRNA species can be 
translated into different protein isoforms with potentially tumourigenic effects. Both 
                                               




mutations in cis-splicing regulatory elements and alterations of trans-splicing factors 
may result in abnormal splicing (Figure 4) [20]. Several exonic nonsense mutations4 
are linked to exon skipping [24], and this is the case for the breast-cancer 
susceptibility gene BRCA1(Figure 4A). An inherited mutation of an ESE element in 
BRCA1 prevents binding of ASF/SF2, leading to inappropriate skipping of the 
cassette exon harbouring the mutant ESE [26]. Point mutations, including 
synonymous mutations5, in coding as well as in non-coding regions, may affect splice 
sites and splicing regulatory sequences. Consequently, it is important to consider 
these mutations as well concerning alternative splicing. 
Changes in the concentration, localisation, composition, or activity of trans-acting 
regulatory factors may also result in aberrant splicing. For example, the 
phosphorylation status of SR proteins affects the splicing of the BCL-X pre-mRNA. 
Alternative splicing of this gene results in two isoforms encoding proteins with 
antagonistic functions; a long antiapoptotic isoform (BCL-XL) and a short 
proapoptotic isoform (BCL-XS), with the long isoform being aberrantly 
overexpressed in several tumours (Figure 4B) [27]. 
 
Figure 4. Mutations in cis-splicing regulatory elements and alterations of trans-
splicing factors. (A) A mutation (*) in an exonic splicing enhancer (ESE) of BRCA1 
prevents the binding of ASF/SF2 to the immature transcript, leading to inappropriate exon 
skipping. (B) The phosphorylation status of SR proteins affects the activity of these proteins 
and thus the ratio between proapoptotic (exon skipping) and antiapoptotic (exon inclusion) 
BCL protein [modified from reference 27]. 
                                               
4 Nonsense mutation – any change in DNA that replaces a codon specifying an amino acid with a translation-termination 
codon. 
5 Synonymous mutation – does not change the amino acid encoded by the triplet. 
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1.2.2 Alternative use of promoters and polyadenlyation sites 
The use of alternative promoters and alternative polyadenylation sites also contribute 
to the complexity of the proteome. Most genes have multiple core promoters6 within 
which there are multiple transcription start sites (TSSs)7 [28]. The use of alternative 
promoters enables diversification of transcriptional regulation within a single locus, 
thus playing an important role in the control of gene expression [29]. In Figure 5 A 
and B, two more consequences of alternative promoter usage are depicted. The 
differential use of distinct promoters, with no translation initiation site between them, 
results in the transcription of mRNAs with heterogeneous 5’ untranslated regions 
(5’UTR) coding identical proteins (Figure 5A). The distinct 5’UTRs, however, may 
affect the stability or translation efficiency of the mRNAs. If, on the other hand, there 
is a translation initiation site directly downstream of each of the possible promoters, 
mRNAs encoding distinct proteins can be generated (Figure 5B). Possible 
mechanisms of how a specific promoter is used in preference to others include core 
promoter structure, concentration of cis-regulatory elements, and regional epigenetic 
modifications [29].  
Several oncogenes and tumour suppressor genes have multiple promoters, and 
aberrant promoter usage is in some cases directly linked to cancerous cell growth 
[30,31]. For example, LEF1, which encodes proteins mediating transcriptional 
regulation of WNT/β-catenin target genes, is transcribed by two alternative 
promoters. The upstream promoter produces full-length LEF1 protein, which recruits 
β-catenin to WNT target genes, whereas the other promoter derives a truncated form 
that cannot interact with β-catenin and instead suppresses WNT regulation of target 
genes. The promoter that produces full-length, growth-promoting LEF1 is aberrantly 
activated in colon cancer tissues [30].  
                                               
6 Core promoter – the genomic region that surrounds a TSS or cluster of TSSs, and that is required to recruit the 
transcription initiation complex and initiate the transcription. 




Figure 5. Alternative promoters and polyadenylation. (A) The use of the alternative promoter 
(orange arrow), rather than the upstream promoter, results in the transcription of a shorter pre-
mRNA, and in the use of an alternative first exon (orange box). However, the translation initiation site 
is downstream of both promoters, and the resulting protein products will accordingly be identical. (B) 
The different pre-mRNAs are translated into proteins differing in their N-termini. (C) Recognition and 
utilization of a proximal polyadenylation site, leading to a shortening of the 3’UTR. Micro-RNA 
binding sites in metazoan mRNAs usually lie in the 3’UTR, as indicated by a partially hybridising 
oligonucleotide. The use of possible alternative polyadenylation sites upstream of the depicted 
3’UTR, leading to a truncated protein product with a different C-terminus, is not shown. 
Cleavage and polyadenylation of the pre-mRNA 3’ ends are required for the 
maturation of most transcripts. The pre-mRNA is cleaved ten to 30 nucleotides after 
the polyadenylation signal and a poly(A) tail is then added. A strong polyadenylation 
site is usually located at the end of the 3’UTR. However, nearly all genes have 
additional polyadenylation signals in their 3’UTR (Figure 5C), and differential 
expression of trans-acting factors may explain the use of proximal polyadenylation 
sites. Shortening of the 3’UTR by alternative cleavage and polyadenylation may 
influence mRNA nuclear export and cytoplasmic localisation, as well as mRNA 
stability and translational efficiency [32]. 
Micro-RNAs8 (miRNAs) interact with the 3’UTR of mRNAs and affect protein 
synthesis by mRNA destabilisation and translational repression [33]. Recently, Mayr 
and Bartel compared similarly proliferating nontransformed cell lines and cancer cell 
lines, and found that the cancer cell lines often expressed substantial amounts of 
mRNA isoforms with shorter 3’UTRs [32]. These shorter isoforms usually resulted 
from alternative cleavage and polyadenylation, and exhibited increased stability and 
typically produced a ten-fold more protein, partially due to the loss of miRNA-
mediated repression. In particular, they observed that the expression of the shorter 
                                               




mRNA isoform of the proto-oncogene IMP1, an RNA binding protein that is 
overexpressed in a variety of human cancers, led to far more oncogenic 
transformation than did expression of the full-length annotated mRNA. Alternative 
cleavage and polyadenylation should therefore be considered mechanisms to activate 
cellular proto-oncogenes. 
1.2.3 Global analysis of transcript variation 
Bioinformatic analyses of expressed sequence tag (EST)9 data have provided a rich 
source of information for the identification and analysis of transcript diversity. 
However, EST coverage is typically biased toward the 3’ and 5’ ends of transcripts, 
and in general there are insufficient numbers of sequenced transcripts to infer the 
frequency of specific events, like inclusion or skipping of an alternative cassette exon 
in a given tissue.  
Some of the limitations inherent in the analysis of ESTs have been overcome by the 
development of DNA microarrays. Historically, microarrays have interrogated the 3’ 
ends of RNAs, and used expression at the 3’ end to approximate expression of the 
entire gene. However, this approach assumes that the 3’ end of each gene is clearly 
defined, and does not discriminate between distinct transcripts, as opposed to whole-
transcript expression analysis with exon microarrays or exon-exon junction 
microarrays. 
Prior to the work of the present thesis, the transcriptomes of colorectal carcinomas 
and testicular germ cell tumours, with their normal counterparts, were analysed by the 
GeneChip Exon 1.0 ST Array (Affymetrix, Santa Clara, CA, USA) [35]. This 
microarray contains approximately 5.4 million probes grouped into 1.4 million probe 
sets, which are scattered throughout the genome examining more than one million 
known and predicted exons. A probe selection region (PSR) is the target sequence for 
                                               
9 Expressed sequence tag (EST) – two to eight hundred nucleotide sequence generated from either the 5’ or 3’ end of a 
cDNA clone [34].   
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which a probe set is designed and represents a region of the genome that is predicted 
to act as a single unit of transcriptional behaviour10.  
The ability to measure exon-level differences in gene expression enables indications 
of differential splicing, promoter usage and polyadenylation, as well as existence of 
fusion transcripts. Additionally, results from exon microarray data may indicate the 
existence of novel transcripts, which is an advantage over exon-exon junction 
microarrays [36], that are typically designed against observed or annotated junctions. 
Deep sequencing, also known as high-throughput sequencing or next-generation 
sequencing, of complementary DNA (cDNA) fragments has also been performed in 
the analysis of transcriptomes and is a powerful method for identification of novel 
transcripts [21,37]. 
1.3 Testicular germ cell tumour as a model for stem-cell 
related malignancies 
Testicular cancer is the most common form of cancer among young adult men in the 
Western world11. These patients have a relatively favourable prognosis, with a five-
year survival rate of about 95 %, due to the extreme chemosensitivity of testicular 
cancers. 
The great majority (more than 95 %) of testicular tumours are of germ cell origin, and 
are therefore called testicular germ cell tumours (TGCT). Three epidemiologically, 
clinically and histologically distinct forms of TGCTs have been described; the 
teratomas and yolk-sac tumours of neonates and infants (type 1), the spermatocytic 
seminomas of elderly men (type 3), and the type 2 seminomas and non-seminomas of 
adolescents and young adults, which is the most common [38]. 
                                               
10 Often, each PSR is an exon, however, due to potentially overlapping exon structures or alternative splice site usage, 




The type 2 TGCTs develop after puberty from pre-malignant, non-invasive 
intratubular germ cell neoplasia (IGCN) [39], which is thought to arise during foetal 
development from a primordial germ cell (PGC) or gonocyte [40]. IGCN has the 
ability to develop into two histologically distinct tumours, seminomas and non-
seminomas. The seminomas are composed of a uniform population of 
undifferentiated cells, which resemble the PGC, whereas the heterogeneous group of 
non-seminomas consists of embryonal carcinoma (EC), choriocarcinomas, yolk sac 
tumours, and teratomas (Figure 6). The pluripotent EC cells can be regarded as the 
stem cell population of the non-seminomas, as they have the ability to differentiate 
into the other histological subgroups of non-seminomas [41]. Understanding the 
biology of EC cells may thus bring knowledge not only about TGCTs, but also 
concerning cancer stem cells12. 
 
Figure 6. Development of TGCT. It is thought that intratubular germ cell neoplasia (IGCN) 
arises during foetal development by malignant transformation of a primordial germ cell 
(PGC) or gonocyte (GC). After puberty, IGCN may develop into invasive cancer in the form 
of seminoma (Sem) or embryonal carcinoma (EC) histological subtypes. The pluripotent EC 
cells have the potential to differentiate into distinct extra-embryonic tissues, like 
choriocarcinomas (Cc) and yolk sac tumours (YST), in addition to embryonic and somatic 
tissues (teratomas, Ter). Together, EC, Cc, YST, and Ter constitute the heterogeneous 
group of non-seminomas. The origin of non-seminomas is somewhat uncertain; either, 
embryonal carcinomas develop directly from IGCN, or they develop through a seminoma 
stage [43]. 
More than 80 % of TGCT genomes are characterised by the presence of 
isochromosome 12p13 [44], i(12p), and most i(12p) negative TGCTs have 
                                               
12 Cancer stem cell – a cell within a tumour that possesses the capacity to self-renew and to cause the heterogeneous 
lineages of cancer cells that comprise the tumour [42]. 
13 Isochromosome – an abnormal chromosome with two identical arms due to duplication of one arm and loss of the other. 
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amplifications of 12p sequence. Additionally, the general TGCT genome is hypo- to 
hypertriploid with extensive chromosome instability, and has erased parental 
imprinting. Furthermore, seminomas and non-seminomas have distinct epigenetic 
phenotypes. Whereas CpG island methylation is virtually absent in seminomas, the 
degree of methylation in non-seminomas is similar to that identified in other solid 
malignancies [as reviewed in reference 45]. 
Embryonic stem (ES) cells are derived from the inner cell mass (ICM) of the 
blastocyst stage in early embryogenesis. These self-renewing cells progressively 
adapt to the culture conditions during continuous passages14 and acquire an increased 
growth rate. Culture adapted ES cells are karyotypically abnormal, and the most 
frequently observed karyotypic changes are gains of materials from chromosomes 12, 
17 and X, and similar non-random, recurrent alterations are seen in TGCTs as well 
[46]. Hence, the progressively culture adaptation of ES cells in vitro probably reflects 
malignant transformation in vivo.  
EC and ES cells also show several other phenotypic resemblances, the most profound 
being pluripotency and the sharing of common cell surface markers and general gene 
expression programmes. Altogether, EC is commonly considered a malignant 
caricature of ES cells [47]. In this thesis, ES cells were considered a normal 
counterpart to EC cells in particular, and to TGCTs in general. 
In this thesis, both early (karyotypically normal) and late passages (culture adapted 
and karyotypically abnormal) ES cell lines were included and compared to EC cell 
lines and TGCT tissue samples. ES cell line passages up to approximately 50 can be 
considered early, but this number is not well defined. 
                                               




1.4 Colorectal cancer 
World-wide, more than one million people are diagnosed with colorectal cancer 
(CRC) each year [48]. The corresponding number in Norway is about 3500, and CRC 
is the most common form of sex-independent cancer [49].  
The majority of colorectal cancers occur sporadically, with less than five percent of 
the incidences being due to single hereditary components, as is the case for the 
autosomal dominant disorders Lynch syndrome and familial adenomatous polyposis 
(FAP). The relative life-time risk of developing CRC for Lynch syndrome and FAP 
individuals is 80 % and 100 %, respectively.  Lynch syndrome, also known as 
hereditary non-polyposis colorectal cancer (HNPCC), is caused by a germ line 
mutation in one of the components of the DNA mismatch repair system (MMR), most 
commonly MSH2 or MLH1 [50]. FAP is linked to a germ line mutation in the tumour 
suppressor gene APC, which is involved in the degradation of β-catenin. Mutations 
leading to aberrant splicing of the genes associated with Lynch syndrome and FAP 
have been identified [51,52]. 
Colorectal cancer, sporadic as well as heritable cases, is considered to develop 
through different histopathological steps, resulting in either microsatellite or 
chromosome instable tumours (MSI and CIN, respectively) [53]. A subgroup of CRC 
with epigenetic instability, designated CpG island methylator phenotype (CIMP), has 
also been described [54]. CIMP overlaps with both MSI and CIN, but to a higher 
extent with the former. CIMP tumours are associated with promoter 
hypermethylation of a large number of genes, including MLH1, leading to sporadic 
MSI tumours. However, CIMP is characterised by distinct pathological, clinical, and 
molecular genetic features [55]. 
CIN tumours account for the majority (~ 85 %) of colorectal carcinomas, and are 
characterised by allelic losses, chromosomal amplifications and translocations [55]. 
Moreover, these tumours are most frequently found in the left side of the colon, and 
inactivation of the tumour suppressor genes APC and TP53, in addition to activation 
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of the proto-oncogene KRAS, are more prevalent among CIN tumours compared to 
MSI tumours [55]. 
Inactivation of the MMR system in sporadic MSI tumours is usually caused by 
epigenetic silencing of MLH1, leading to frameshift mutations and base-pair 
substitutions within randomly repeated nucleotide sequences known as 
microsatellites. The majority of microsatellites are located in non-coding areas; 
however, some tumour suppressor genes, e. g. TGF-βRII and BAX, harbour 
microsatellites in their coding sequences, leading to frequent frameshift mutations. 
Frameshift mutations of CTNNB1 are also often seen in MSI tumours [55]. 
Additionally, MSI, and to a higher extent CIMP, is associated with an activating 
mutation of the proto-oncogene BRAF [56]. MSI tumours are generally located in the 
right colon, and MSI patients have a better prognosis than stage-matched CIN 
patients. Furthermore, MSI is associated with female gender and poor differentiation 
[55]. 
In 1932, Cuthbert E. Dukes proposed a classification system according to the extent 
of spread of the tumour [57] (Figure 7). However, the TNM staging system for 
colorectal cancer, first introduced by Pierre Denoix, is also commonly used. This 
describes three characteristics of the cancer; the extent of primary tumour (T) 
invasion, the degree of spread to regional lymph nodes (N), and whether or not 
metastasis (M) to distant organs is observed. Numbers (increasing with severity) are 




Figure 7. Modified Dukes’ staging. In Dukes’ A colorectal cancer, the tumour is confined 
to the mucosa and submucosa of the bowel wall, while in Dukes’ B cancer, the tumour has 
penetrated into the muscle layer. In Dukes’ C, cancer cells have spread to local lymph 
nodes, whereas in patients with Dukes’ D, the cancer has metastasised to distant organs. 
The prognosis among CRC patients depends to a great degree on the tumour stage at 
the time of diagnosis. Patients with a localised tumour have a 15-year survival close 
to 90 % (Dukes’ A and B), and the corresponding number for patients diagnosed with 
regional spread is 65 % (Dukes’ C). On the other hand, patients with distant 
metastases have a five-year survival of only about 10 % (Dukes’ D) [49]. Hence, 
diagnosis at an early time point is important. However, there is no good screening 
strategy for colorectal cancer apart from colonoscopy. In this thesis, novel cancer 
specific transcripts were sought which may be implemented as diagnostic biomarkers 




The main aim of this thesis is to discover novel cancer-specific transcript variants 
which may serve as diagnostic biomarkers.  
Specifically, we aim to establish an experimental pipeline to validate the existence of 
different transcript variants which were initially suggested by exon microarray data. 
Further, we intend to describe the biologically validated transcript variants in clinical 
samples from CRC and TGCT patients for presence of cancer-specificity, or whether 
there is a significantly difference in the ratios between alternative transcripts already 
present in healthy tissues. 
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3. Materials and methods 
3.1 Materials 
3.1.1 Cell lines 
The project involved analyses of six colon carcinoma cell lines (HT29, HTC15, 
LS1034, RKO, SW48, and SW480), five EC cell lines (TERA1, TERA2, NTERA2, 
2102Ep, and NCCIT), and the two ES cell lines H14 and Shef5, both early and late 
passages. After the exon arrays, no more RNA was available from Shef5 early 
passage, and consequently this sample was not included in the validation. Two EC 
cell lines, NTERA2 and 2102Ep, treated with retinoic acid to induce differentiation, 
were also included. RNA from all the colon carcinoma and ES cell lines, in addition 
to the samples from the three EC cell lines used to obtain exon array data, was 
isolated by the All prep DNA/RNA mini kit (Qiagen Co., Valencia, CA, USA). 
Trizol (Invitrogen, Carlsbad, CA, USA) was used in the isolation of RNA from the 
other cell lines. The end product of both methods is the total RNA fraction, but the 
column-based method do not preserve RNA fragments less than 200 nucleotides. 
Culturing and sorting of the ES and EC cell lines were carried out in collaboration 
with the group of Peter Andrews at the Centre for Stem Cell Biology and Department 
of Biomedical Science, University of Sheffield. 
3.1.2 Patient samples 
Testicular germ cell tumours 
Twenty-five TGCT samples, representing the five histologically different subtypes, 
were included in the project, in addition to six pre-malignant IGCN samples and five 
normal testicular parenchyma tissue samples. Frozen tissue sections stained with 
haematoxylin and eosin were evaluated by an expert pathologist to determine the 
Materials and methods 
 28
histological subtype of each of the TGCTs and IGCNs. For 23 of the samples, a 
frozen section of the exact same tissue piece as used in this study was evaluated, 
whereas for the remaining eight samples, the section was made from a neighbouring 
tissue piece. The surgical specimens were collected from several hospitals in 
Southern Norway during the years 1985 to 1992. RNA was isolated by Trizol 
(Invitrogen). 
Colorectal cancer 
One-hundred-and-seven primary colorectal carcinoma samples, of which 58 Dukes’ 
B and 49 Dukes’ C, were included in this study. Ninety-nine of these samples were 
collected at seven hospitals in the South-Eastern part of Norway between 1987 and 
1989, and the remaining eight samples were collected at Aker University hospital in 
2005 and 2006. From the same series as the eight last mentioned colorectal carcinoma 
samples, ten normal colorectal tissue samples were also included. After the exon 
arrays, there was no more RNA available from two normal and two cancer tissue 
samples. Consequently, these four samples were not included in the validation. RNA 
from cancer tissues was isolated by the All prep DNA/RNA mini kit (Qiagen), and 
total RNA from normal tissue samples was isolated by the RiboPure kit (Applied 
Biosystems/Ambion, Foster City, CA, USA).  
3.2 Whole-transcript Expression Analysis 
The processing of the exon microarrays and subsequent primary data analysis were 
performed by others in the research group. Descriptions of these analyses are yet 
included to facilitate an understanding of the completeness of the study.  
In the TGCT study, exon arrays were run of RNA isolated from two ES cell lines 
(Shef5 and H14, both early and late passages), and three EC cell lines (NCCIT, 
NTERA2, and NCCIT). Exon arrays were also run of all the colon tissue samples 
mentioned in 3.1.2, except the cancer tissue samples collected at the Aker University 
Hospital in 2005 and 2006.  
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Total RNA was purified as described in section 3.1, and the RNA quality was 
assessed on Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, 
USA). For each of the samples, one microgram of high quality RNA was used as 
input for the Affymetrix GeneChip Whole Transcript (WT) Sense Target Labeling 
Assay. Briefly, the samples were amplified and labelled according to the 
manufacturer’s protocol. The resulting complementary DNA (cDNA) was then 
hybridised to the Affymetrix Human Exon 1.0 ST Array using the Hybridization 
Control Kit (Affymetrix) according to the manufacturer’s protocol. Subsequently, the 
arrays were washed and stained using the Hybridization Wash and Stain Kit 
(Affymetrix) before scanning, all again according to the protocol. 
The scanned array image was gridded by the Affymetrix GeneChip Operating 
System, which then calculated probe-level intensities from pixel values before storing 
these in CEL files. CEL data files were used as input for XRAY (Biotique Systems, 
Reno, NV, USA) to find significant differences in gene expression and transcript 
isoforms between the two groups. Quantile normalization and GC based background 
correction was applied, while p-values were corrected by using Benjamini and 
Hochberg False Discovery Rate (FDR).  
In the TGCT study, exon-wise plots of the candidate genes with the most significant 
differences in exon usage were manually examined to generate a shortlist of genes for 
validation. The number of differential exon-level inclusions predicted by XRAY 
(Biotique Systems) in the colon cancer study were considered too numerous for 
manual inspection. Consequently, the FIRMA (Finding Isoforms using Robust 
Multichip Analysis) algorithm [58], found in the aroma.affymetrix BioConductor 
package, was utilized. In brief, the FIRMA scores each exon as to whether its probe 
signals deviate from the expected gene expression level. Accordingly, a difference in 
FIRMA score between two groups for a specific exon implies an event resulting in 
differential exon inclusion. The FIRMA score rankings were combined with XRAY 
p-values prior to manual accession of the candidates (Figure 8). 
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3.3 Validation of exon microarray data 
Genes for which the initial microarray data analysis revealed a potential difference in 
the transcript structures were further evaluated both by use of in silico tools, as well 
as by wet-lab analyses (Figure 8). In the following, methods used to validate 
candidate cancer-specific transcripts will be described. 
 
Figure 8. Filtering of candidate genes. In this figure, the CRC and TGCT studies are 
depicted to the left and right of the workflow, respectively. The starting point in both studies 
was the collection of all core probe sets, which refer to probe sets that are supported by the 
most reliable evidence from RefSeq and full-length mRNA GenBank records containing 
complete coding sequence information. Exon microarray data obtained from the two 
different groups were compared in the XRAY software (malignant versus normal tissues 
from colon and rectum, and ES versus EC cell lines), and significantly differential exon-level 
inclusions were listed. Then, the exon-wise plots were manually examined prior to visual 
inspection of the probe sets in the X:Map genome browser (mapping of probe sets to 
biological exons). In the CRC study, the XRAY p-values were combined with FIRMA score 
differences prior to examination of the plots. Subsequently, relevant assays were designed 
and the candidates were analysed in the laboratory. Finally, a total of six (three in each 
study) validated differential expression of transcript isoforms remained. Several candidate 
genes were rejected in each step. The master project involved examination of some of the 
exon-wise plots, in addition to all subsequent steps. 
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3.3.1 In silico exploration of candidate transcript variants 
The interesting probe set(s) for each candidate gene, in addition to the surrounding 
probe sets, were searched for in the X:Map Genome Browser15. This was performed 
to map the PSRs to known biological exons and to visualise and inspect the candidate 
differentially included exon in annotated transcripts. The visual inspection of the 
probe sets in a genomic context is crucial with respect to designing a validation assay 
involving all transcript variants which potentially could be the cause of the divergent 
exon-wise profile, as the profiles do not reveal which exons are actually physically 
linked. Additionally, the X:Map Genome Browser gave warnings when searching for 
probe sets known to be cross-hybridising, and if this was the case for the probe set 
destined for validation, the respective candidate gene was rejected. Several other 
candidate differentially exon-level expressions were also rejected at this step, e. g. 
candidate events involving differential expression of an area in the middle of a known 
exon, as such events are relatively unlikely to be validated. 
The visualisation of the probe sets in X:Map was coupled with the design of 
validation assays (RT-PCR primers), and probe sequences given in X:Map were 
searched for in the Ensembl Genome Browser16. Exon sequences, and in some cases 
intron sequences as well, were derived from Ensembl, and primers were designed. 
3.3.2 Reverse transcriptase PCR (RT-PCR)  
Primer design 
In most cases, RT-PCR primers were designed to anneal to constitutive exons 
flanking the area of interest (Figure 9). This works well for simple cassette exons and 
alternative 5’ and 3’ splice sites, but other types of alternative splicing and 
transcription start/stop events are challenging and require more thoughtful primer 
                                               
15 http://xmap.picr.man.ac.uk  
16 http://www.ensembl.org  
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design, and this will be discussed in section 5.3. The forward and reverse primers 
were designed using the Primer 3 software17 with default settings, and possible 
primer secondary structures and dimers were visualised and evaluated using the 
NetPrimer software18. All primers were purchased from MedProbe (Oslo, Norway). 
Primer information is available in Appendix I. 
 
Figure 9. Primer design for RT-PCR validation of alternative splicing events. Primers 
are represented by purple arrows. The size of the RT-PCR product depends on whether the 
alternative exon, represented by an orange box, is included or skipped in the mature RNA. 
Experimental assay 
First-strand cDNA synthesis was performed using the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). The RNA sample was diluted in RNase free 
water (Sigma-Aldrich, St. Louis, MO, USA) to an end concentration of 200 ng/µl in a 
total volume of 10 µl. Then 10 µl of the 2 x reverse transcription master mix 
containing RT buffer, dNTP mix, random primers, MultiScribe reverse transcriptase, 
and RNase free water (Sigma-Aldrich) was added. The reaction mix was incubated 
on a MJ Mini Gradient Thermal cycler (BIO-RAD, Hercules, CA, USA), first at 25 
°C for ten minutes (primer annealing), then cDNA was allowed to synthesize at 37 °C 
for two hours, prior to reaction termination at 85 °C for five seconds. It is assumed 
that all the RNA is converted to cDNA in the reaction, hence the concentration of 
cDNA become 100 ng/µl. The cDNA was diluted to an end concentration of 50 
ng/µl. 
                                               
17 http://frodo.wi.mit.edu  
18 http://www.premierbiosoft.com  
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The RT-PCR reaction was performed using the HotStarTaq DNA Polymerase Kit 
(Qiagen). One reaction mix contained 1 x PCR buffer, 200 µM of each of the dNTPs, 
160 nM of each of the primers, one unit of HotStarTaq DNA Polymerase, and 50 ng 
of template cDNA. The PCR buffer includes MgCl2 to a final concentration of 1.5 
mM per reaction. If a concentration of Mg2+ of 3.0 mM was wanted, more MgCl2 was 
added. The total volume was adjusted to 25 µl with Milli-Q water (Milli-Q Biocel 
System, Millipore Corporation, Billerica, MA, USA). The cDNA was amplified in a 
Robocycler Gradient 96 (Stratagene, La Jolla, California, USA), and the cycling 
conditions are shown in the table below (Table 1). 
Table 1. Thermal cycling conditions RT-PCR. 
      Additional comments 
Initial activation step: 15 min 95 °C Activation of the 
   HotStarTaq DNA Polymerase 
3-step cycling    
Denaturation: 30 sec 95 °C  
Annealing: 1 min Variable Depends on the Tm of primers 
Extension: 2 min 72 °C 4 min for products > 2 kb (but < 4 kb) 
Number of cycles: 27 or 30  Prior to fluorescent detection: 27 
   Prior to analysis on an agarose gel: 30 
Final extension: 6 min 72 °C   
 
The number of cycles in the PCR reaction was determined by the method to be 
utilized to study the PCR products. Before capillary electrophoresis with fluorescent 
detection, the standard was to run 27 cycles, and prior to analysis on an agarose gel, 
the standard was 30 cycles. These fixed numbers of cycles were in some cases 
adjusted due to variation in the reaction efficiencies. 
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3.3.3 Real-time RT-PCR 
Primer and probe design 
For all the candidate genes destined for real-time analysis, except ASPH, there was no 
pre-designed TaqMan Gene Expression Assay (Applied Biosystems) available. For 
two of these, ABCC3 and PMF1, the Primer Express Software v3.0 (Applied 
Biosystems) was used to design primers and probe. For the genes SLC39A14, SPAG9 
and DNMT3B, we were not able to modify the settings of this software to obtain a 
useful assay. In these cases, the Primer3 software was used with default settings to 
design primers, and the probe was manually designed. The probe was selected based 
on the parameters given by the Primer Express Software. The primer and probe 
melting temperatures and GC 
contents were analysed by the 
Primer Probe Test Tool found 
in the Primer Express Software, 
and if necessary, modifications 
were done. The commercial 
TaqMan minor groove binder 
(MGB) assay, in addition to the 
custom designed MGB probes, 
were purchased from Applied 
Biosystems, whereas the 
primers were purchased from 
MedProbe. The chemistry of 
the TaqMan assays is described 
in Box 1. 
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Experimental assay 
The cDNA synthesis was performed using the same kit as previously described. 
The pre-designed commercial quantitative RT-PCR assay was carried out in a fast 
optical 96-well reaction plate (Applied Biosystems), and the custom-designed assays 
were performed in standard 96- or 384-well optical reaction plates (Applied 
Biosystems). Different TaqMan master mixes, reaction volumes, and thermal cycling 
conditions were used with regard to whether the reactions should be carried out in 
fast or standard, or 384- or 96-well plates. The TaqMan Fast Universal PCR Master 
Mix (No AmpErase UNG, Applied Biosystems) was utilized in fast reactions, and the 
TaqMan Universal PCR Master Mix (AmpErase UNG, Applied Biosystems) was 
used in standard reactions. The final concentrations of master mix, forward and 
reverse primers, and probe in the standard reactions were 1 x, 0.9 µM of each, and 0.2 
µM, respectively. In the fast reaction, the end concentrations of master mix and 
TaqMan Gene Expression Assay (primers and probe) were both 1 x. A total reaction 
volume of 20 µl was used when the reactions were performed in 384- and fast 96-
well plates, as distinct from standard 96-well plates, where the total volume per 
reaction was set to 25 µl. RNase free water (Sigma-Aldrich) was added to the correct 
total volume. In each setup, the amount of starting material (cDNA) was 10 ng.  
Multiplex real-time RT-PCR was done as well, adding one primer set, and two 
different probes with distinct dyes (FAM and VIC), in the same well. In these cases, 
the concentration of each of the primers where doubled compared to a standard setup, 
whereas the remainder (plate, master mix, final concentrations, volume, and thermal 
cycling conditions) was the same as for a standard assay.  
The plates were incubated, and fluorescence measured, on an ABI 7900HT Fast Real-
Time PCR System (also known as a “TaqMan”; Applied Biosystems). The thermal 
cycling conditions differed in the fast and standard reactions (Table 2). 
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Table 2. Thermal cycling conditions real-time RT-PCR. 
    Standard Fast 
UNG activation: 50 °C 2 min - 
Polymerase activation: 95 °C 10 min 20 sec 
Denaturation: 95 °C 15 sec 1 sec 
Annealing and extension: 60 °C 1 min 20 sec 
Number of cycles:   40 40 
 
The pipetting robot EpMotion 5075 (Eppendorf, Hamburg, Germany) was used to 
pipette template to the wells in 384 plates, but the 96-well plates were set up 
manually. Master mix was distributed manually with a multi-channel pipette. 
A standard curve was produced by serially diluted universal human reference (UHR) 
cDNA, synthesised from UHR RNA (Stratagene), of known concentrations. All 
samples were run in triplicates, and two endogenous control gene assays, ACTB and 
GUSB (both Applied Biosystems), were performed on all the samples in the TGCT 
study. In the colon cancer study, only the ACTB assay was utilised. 
3.3.4 Detection of PCR products 
Agarose gel electrophoresis 
PCR products were separated according to size by agarose gel electrophoresis. The 
gels were made with 2 % agarose for separation of most products, but in some cases a 
3 % gel was made to separate the bands more clearly. Eight or twelve grams of 
agarose (BioRad, Hercules, CA, US) were heated in 400 ml of 1 x Tris-acetate EDTA 
(TAE) buffer to make a two or three percent gel, respectively. The intercalating dye 
ethidium bromide (GeneChoice, Frederick, USA) was added to make the PCR 
products visible when illuminated with ultraviolet light. Ten to 25 µl of PCR product 
was mixed with the gel loading buffer bromophenol blue (one fifth of the volume of 
PCR product) and loaded onto the gel. The electrophoresis was run at 200 V for 25 to 
30 minutes.  
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Capillary electrophoresis of fluorescently labelled PCR product 
Prior to the capillary electrophoresis, a PCR was performed in which either the 
forward or reverse primer was labelled with the fluorophore 6-FAM. In each well of a 
96-well optical reaction plate (Applied Biosystems), 0.5 µl of PCR product was 
mixed with 9.0 µl highly deionised (Hi-Di) formamide (Applied Biosystems) and 0.5 
µl of a fluorescently labelled size standardised DNA ladder. The plate was then 
sealed with a 3100 Genetic Analyzer Plate Septa (Applied Biosystems), and the DNA 
was denatured for five minutes at 95 °C. Subsequently, the plate was placed in a 96-
well plate base and inserted into a fully automated ABI 3730 DNA Analyzer 
(Applied Biosystems). Depending on the expected fragment sizes, either the ladder 
GeneScan 500 LIZ Size Standard or GeneScan 1200 LIZ Size Standard (Applied 
Biosystems) was chosen. The 500 LIZ was used with fragments up to 600 bp in 
length, and the LIZ 1200 was chosen when 600 to 1000 bp PCR products were 
expected. 
The samples were analysed using the software GeneMapper v3.7 (Applied 
Biosystems). See section 3.3.5 for information on capillary electrophoresis. 
3.3.5 DNA Sequencing 
Purification of template DNA 
PCR products separated on an agarose gel were cut out of the gel and purified using 
the MinElute Gel Extraction Kit (Qiagen) according to the manufacturer’s protocol. 
DNA fragments purified with the MinElute system are ready for direct use in several 
applications, including ligation and transformation, and sequencing.  
Sequencing reaction 
Each sequencing reaction consisted of 1.0 µl of PCR product eluted from agarose gel, 
1.5 µl of BigDye 5 x sequencing buffer (Applied Biosystems), 1.0 µl BigDye 
Terminator v3.1 premix (Applied Biosystems), 150 nM of forward or reverse primer, 
and Milli-Q water (Millipore) to a total volume of 10 µl. The reactions were 
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incubated at 96 °C for two minutes, followed by 25 thermal cycles of 15 seconds at 
96 °C, five seconds at 50 °C, and four minutes at 60 °C. The thermal cycling was 
performed on a Robocycler Gradient 96 (Stratagene). The premix contains 
polymerase, dNTPs, and ddNTPs. The different ddNTPs are modified with distinct 
fluorescent labels. 
Product purification 
After the sequencing reaction, unincorporated dye terminators and other small 
molecules were removed. This was done by centrifuging the products through a 
Sephadex column, which separates molecules according to size. Small molecules will 
diffuse into the pores of the column, thus their passage through the column is 
delayed. Larger molecules, on the other hand, like the sequence products, will pass 
directly through the column. The column was made by loading Sephadex G-50 
Superfine powder (GE Healthcare, Little Chalfont, Buckinghamshire, UK) on to a 
Multiscreen 96-Well Filtration Plate (Millipore). Three-hundred µl of Milli-Q water 
(Millipore) was added to each well, and the Sephadex was then allowed to swell for 
two hours, prior to centrifugation at 910 relative centrifugal force (rcf) for five 
minutes. To rinse the columns, 150 µl water was added to the wells before another 
round of centrifugation at 910 rcf for five minutes. Ten µl Milli-Q water (Millipore) 
and ten µl sequence reaction product was loaded on to each column, prior to 
centrifugation at 910 rcf for six minutes. The samples were collected in the wells of a 
96-well optical reaction plate (Applied Biosystems), and the plate was then sealed 
with a 3100 Genetic Analyzer Plate Septa (Applied Biosystems). Subsequently, the 
plate was placed in a 96-well plate base and inserted into a fully automated ABI 3730 
DNA Analyzer (Applied Biosystems). 
Capillary analysis 
In the ABI 3730 DNA Analyzer, the various fluorescent labelled fragments of 
different lengths are separated according to size in a 48-capillary array filled with 
POP7 polymer (Applied Biosystems). As the sequencing products pass the detection 
window, a laser beam excites the dye molecules and causes them to fluoresce. The 
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Data Collection software interprets the fluorescence data and displays them as 
electropherograms. The samples were analysed using the Sequencing Analysis 5.2 
software (Applied Biosystems) and the free DNA sequencing chromatogram trace 
viewer FinchTV v1.4 (Geospiza, West Harrison, Seattle, USA). 
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4. Results 
To identify novel transcript structures in cancer, as well as skewed ratios between 
pre-existing transcript variants, and evaluate their potential as cancer biomarkers, 
exon microarray data of two different cancer types were investigated. EC and ES cell 
lines were included to identify malignancy-specific transcript variants in a stem cell 
context (part 4.1), while malignant and normal tissues from colon and rectum were 
included to identify novel biomarkers for CRC (part 4.2). 
4.1 Transcript variation in testicular germ cell tumour 
The exon microarray data obtained from the ES and EC cell lines were analysed by 
others using the XRAY software for identification of differential expression at the 
gene and exon levels (only exon level analyses are discussed in this thesis). Five-
hundred-and-sixty-five candidate events at the exon level had p-values of < 1 · 10-4, 
and were short-listed as candidates for malignancy-specific transcript variants. 
Subsequent manual examination of the exon-wise plots, and visual inspection of the 
probe sets in a genomic context, reduced the candidate list down to 24, which were 
selected for validation in the lab. Three of these candidates were confirmed, and are 
presented in the following (Table 3). 
Table 3. Validated candidate genes in the TGCT study. Overview of the different 
transcript variants and the lengths of the PCR products representing them. 
Gene Transcript variant Expression PCR product 
Short-exon-four High in NCCIT and 2102Ep 111 bp PMF1 
Long-exon-four High in Shef5, H14 and NTERA2 172 bp 
Short High in NCCIT and NTERA2 247 bp DNMT3B 
Long High in Shef5, H14 and 2102Ep 436 bp 
Short High in EC (NCCIT, 2102Ep and NTERA2) 180 bp ZNF195 




4.1.1 Polyamine-modulated factor 1 (PMF1) 
PMF1 is transcribed from the plus strand of cytogenetic band 1q22. The Ensembl 
Genome Browser19, release 56, has annotated nine transcript variants of PMF1. 
The exon microarray data are shown in Figure 10A. The exon-wise plot suggests that 
the overall expression of PMF1 is somewhat higher in the EC cell lines 2102Ep and 
NCCIT compared to the ES cell lines Shef5 and H14. However, a probe set 
interrogating the 5’ part of exon four shows the contrary regarding the expression, 
which implies differential splicing. However, notice that the EC cell line NTERA2 
has an exon-wise profile resembling that of the ES cells. Two known splicing events, 
resulting in varying inclusion of sequence from exon four due to an alternative 3’ 
splice site, were assumed to be responsible for this profile. Both standard and real-
time RT-PCR assays were designed to validate the structure of the transcripts and 
their respective quantities (Figure 10B).  
 
Figure 10. PMF1 (ENSG00000160783). (A) Expression levels (log-2) of the different PSRs 
(often corresponding to the distinct exons) for PMF1 as seen from exon microarray data. 
                                               
19 http://www.ensembl.org  
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The green and red lines represent the averages of four ES (Shef5 and H14, both early and 
late) and two EC cell lines (2102Ep and NCCIT), respectively. The EC cell line (NTERA2), 
which has an exon-wise profile resembling that of the ES cells, is plotted alone. Exons one 
to five are numbered according to the transcript ENST00000368277; however, exons 6’ and 
7’ are not present in this transcript, but in other transcripts of this gene. (B) Two known 
splicing events assumed to be responsible for the interesting exon-wise plot are shown. The 
green and red lines represent the splicing events dominating in ES and EC cells, 
respectively. Primers for standard RT-PCR were designed to anneal to exon three and to 
the common part of exon four (purple arrows). The real-time RT-PCR (TaqMan) assay was 
designed as depicted, with a probe in the splice junction primarily present in the EC 
samples. 
For PMF1, we chose standard RT-PCR and capillary electrophoresis of fluorescently 
labelled PCR products as a first-line validation, and included five of the same 
samples as examined by the exon microarray analysis (Figure 11). Here, we saw that 
the two ES cell lines (H14 and Shef5 late), and the EC cell line with an exon-wise 
profile resembling that of the ES cell lines (NTERA2), expressed the long-exon-four 
variant, resulting in a PCR product of 172 bp. However, the PCR product 
representing the short-exon-four transcript (111 bp) was barely visible. Conversely, 
for NCCIT and 2102Ep there was a shift towards the short-exon-four transcript, even 
though the long-exon-four transcript was still present at a level comparable to the 
other cell lines. 
 
Figure 11. Validation of PMF1 transcript variants by capillary electrophoresis of 
fluorescently labelled PCR products. Depicted to the left are the three cell lines (H14, 
Shef5 and NTERA2) which based on the microarray data were expected to express 
relatively more of the long-exon-four, and less of the short-exon-four transcript, compared to 
NCCIT and 2102Ep (shown to the right). The graphs indicate the amount of RT-PCR 
product (y-axis; fluorescent intensity) relative to the RT-PCR product size in base pairs (x-
axis). The lengths of the detected RT-PCR products were in accordance with the expected 
long and short-exon-four transcripts (172 bp and 111 bp, respectively). 
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On the basis of these results, we decided to investigate these transcripts further by 
expanding the sample series to include a series of clinical TGCT, IGCN and normal 
tissue samples, as well as ES and EC cell lines. In these samples, we analysed PMF1 
expression quantitatively, by real-time RT-PCR specifically targeting the short-exon-
four transcript. The ratio between the amounts of this candidate cancer-specific 
transcript versus the long-exon-four transcript was determined by the RT-PCR assay 
already described. The short-exon-four transcript was detected by real-time RT-PCR 
in samples of several different histological subtypes. Interestingly, the samples 
separated clearly into two groups when these quantitative data were plotted against 
the transcript variant ratios (Figure 12). However, the groups were not separated by 
any obvious characteristics such as whether they originated from cancer versus 
normal samples, different histological subtypes (although all teratomas and 
seminomas, except one sample, are present in the group to the right), nor if they 
originated from tissue or cell line. Nevertheless, the samples were sorted along the x-
axis as expected from the exon microarray data; the ES cell lines, in addition to the 
EC cell line NTERA2, form a part of the group down to the left, while 2102Ep and 




Figure 12. Quantitative and variant-specific PMF1 expression data in a series of 
clinical TGCT, IGCN and normal tissue samples, in addition to ES and EC cell lines. 
Quantitative TaqMan data from the candidate cancer-specific transcript variant (short-exon-
four transcript) are plotted against fluorescence intensity ratios (originating from capillary 
electrophoresis) between the short versus long-exon-four transcripts (both log-2). Several 
samples were not detected by the real-time RT-PCR, and these were denoted NA (not 
available). 
4.1.2 DNA (cytosine-5)-methyltransferase 3β (DNMT3B) 
DNMT3B is transcribed from the plus strand of cytogenetic band 20q11.21. The 
Ensembl Genome Browser, release 56, has annotated eight transcript variants of 
DNMT3B. 
The exon microarray data are shown in Figure 13A. Two probe sets interrogating 
exons 20 and 21 proposes differential splicing, as exons 20 and 21 seem to have a 
relatively higher level of inclusion in ES cells, in addition to the EC cell line 2102Ep, 
compared to EC cells. Alternative inclusion or skipping of the two consecutive 
cassette exons 20 and 21 were suggested to be responsible for this profile. Both 
standard and real-time RT-PCR assays were designed to validate the structure of the 




Figure 13. DNMT3B (ENSG00000088305). (A) Log-2 expression levels of the different 
PSRs for DNMT3B as seen from exon microarray data. The green and red lines represent 
the averages of four ES and two EC cell lines, respectively. The EC cell line (2102Ep) with 
an exon-wise profile resembling that of the ES is plotted alone. The exons are numbered 
according to ENST00000201963. (B) Two known splicing events assumed to be 
responsible for the interesting exon-wise plot are shown. The green and red lines represent 
the splicing events dominating in ES and EC, respectively. Standard RT-PCR primers were 
designed to anneal to the flanking constitutive exons 19 and 22. The real-time RT-PCR 
assay was designed with a probe in the splice junction primarily present in the EC samples. 
In the first-line validation, standard RT-PCR and capillary electrophoresis were 
performed on five of the same samples as examined by the exon microarray analysis 
(Figure 14). Here, we saw that all the cell lines expressed both transcript variants. 
However,  the two ES cell lines (H14 and Shef5 late), and the EC cell line with an 
exon-wise profile resembling that of the ES cells (2102Ep), expressed more of the 
exons 20 and 21 inclusion transcript variant (from now on denoted “long”, resulting 
in a PCR product of 436 bp) and less of the exons 20 and 21 skipping transcript 
variant (denoted “short”, resulting in a PCR product of 247 bp), while the opposite 




Figure 14. Validation of DNMT3B transcript variants by capillary electrophoresis of 
fluorescently labelled PCR products. Depicted to the left are the three cell lines (H14, 
Shef5 and 2102Ep) which based on the exon microarray data were expected to express 
relatively more of the long variant (exons 20 and 21 included), and less of the short variant 
(exons 20 and 21 skipped), compared to NCCIT and NTERA2 (shown to the right). The 
lengths of the detected RT-PCR products were in accordance with the expected long and 
short variants (436 bp and 247 bp, respectively). 
The promising transcripts were further investigated by expanding the sample series to 
include a series of clinical TGCT, IGCN and normal tissue samples, as well as ES 
and EC cell lines. In these samples, we analysed DNMT3B expression quantitatively 
by real-time RT-PCR specifically targeting the short variant, and the ratio between 
the amounts of this candidate cancer-specific transcript versus the long variant was 
determined by the RT-PCR assay already described (Figure 15). The short variant 
was detected by real-time RT-PCR in all samples; however, the capillary 
electrophoresis detected only one of the variants in seven of the samples, and hence it 
was not possible to calculate any transcript variant ratio for these samples. This was 
also the case for an additional 20 samples, for which neither the long nor the short 
variant were detected by capillary electrophoresis. In general, the EC samples (cell 
lines as well as the tissue samples) and the ES cell lines showed a higher level of 
DNMT3B expression. Furthermore,  the samples were sorted according to their 
transcript variant ratio as expected from the exon microarray data; the ES cell lines, 
in addition to the EC cell line 2102Ep (as well as the EC tissue samples), showed 




Figure 15. Quantitative and variant-specific DNMT3B expression data in a series of 
clinical TGCT, IGCN and normal tissue samples, in addition to ES and EC cell lines. 
Quantitative TaqMan data from the candidate cancer-specific transcript variant (short 
variant) are plotted against fluorescence intensity ratios between the short versus long 
variants from capillary electrophoresis (both log-2). The capillary electrophoresis detected 
only one of the PCR products in seven of the samples, either the long (five samples) or the 
short (two samples) product. Hence, transcript variant ratios could not be calculated for 
these samples. This was also the case for additional 20 samples (five of each of normal 
testicular parenchyma, IGCN and seminoma, in addition to four teratoma and one yolk sac 
tumour), for which neither the long nor the short variant was detected by capillary 
electrophoresis. 
Additionally, both PCR products were sequenced which confirmed that the expected 




Figure 16. Sequencing of the DNMT3B RT-PCR products. Sequencing of the RT-PCR 
products confirmed that the expected transcript variants were amplified. On the top, 40 
nucleotides in the junction between exons 20 and 21, only present in the long variant, are 
depicted; below, the same is the shown for the exon 19/22 junction belonging to the short 
variant.   
4.1.3 Zinc finger protein 195 (ZNF195) 
ZNF195 is transcribed from the minus strand of cytogenetic band 11p15.4. The 
Ensembl Genome Browser, release 56, has annotated seven transcript variants of 
ZNF195. 
The exon microarray data are shown in Figure 17A. The probe sets interrogating 
exons two, four and six in ZNF195 reveal similar expression of these exons in ES and 
EC cells. However, there are higher expression levels of the probe set targeting exon 
five in the ES cell lines. Two known splicing events, inclusion or skipping of the 
cassette exon five, were supposed to be responsible for this profile. A standard RT-
PCR assay was designed (Figure 17B), and then performed on five of the same 
samples as analysed by the exon microarrays. By this method, all cell lines were 
found to express both variants, resulting in a long (exon five included, 249 bp) and a 
short (exon five excluded, 180 bp) PCR product. However, the ratios between the 
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amounts of short (high in EC) versus long (high in ES) PCR products were greater in 
the three EC cell lines as compared to the ES cell lines, thus reproducing and 
validating the exon microarray data. 
 
Figure 17. ZNF195 (ENSG00000005801). (A) Expression levels of the different PSRs for 
ZNF195 as seen from exon microarray data (log-2). The green and red lines represent the 
averages of four ES cell lines and three EC cell lines, respectively. Exons are numbered 
according to ENST00000005082. (B) Two known splicing events assumed to be 
responsible for the interesting exon-wise plot are shown. The green and red lines represent 
the splicing events dominating in ES and EC cells, respectively. Primers were designed to 
anneal to exons four and six flanking the alternative cassette exon five. 
Subsequently, these transcripts were further investigated by performing the same 
standard RT-PCR assay as in the first-line validation on an expanded sample series 
including clinical TGCT, IGCN and normal tissue samples, as well as ES and EC cell 
lines (Figure 18). Plotting of the fluorescence intensity ratios (short versus long 
variant) against the mean peak heights (originating from the capillary 
electrophoresis), separated the samples into three groups; the ES cell lines, EC (both 
cell lines and tissue samples), and the other histological subgroups of TGCT, in 
addition to IGCN and the normal tissue samples. The ES cells and EC differed in the 
transcript variant ratios, while the other TGCT subgroups, in addition to the IGCN 




Figure 18. Differing ZNF195 transcript variant ratio between EC and ES cells. Results 
from RT-PCR and capillary electrophoresis of fluorescently labelled ZNF195 PCR products 
in a series of clinical TGCT, IGCN and normal tissue samples, in addition to ES and EC cell 
lines. The fluorescence intensity ratios between the short (candidate cancer-specific 
transcript) versus long variants are plotted against the mean peak heights (both log-2). 
4.2 Transcript variation in colorectal cancer 
Exon microarray data obtained from malignant and normal tissues from colon and 
rectum were analysed by others using the XRAY software for identification of 
differential expression at the gene and exon levels (only exon-level analysis are 
discussed in this thesis). The exon-level analyses yielded nearly 1600 candidate 
events, and the XRAY p-values were combined with FIRMA score differences 
between the two sample groups. Due to the great number of candidates, only a small 
portion of the top-scoring events were further investigated by manual examination of 
the exon-wise plots, followed by visual inspection of the probe sets in a genomic 
context. Seven genes were selected for validation in the lab, and three of these 




Table 4. Validated candidate genes in the CRC study. Overview of the different transcript 
variants and the lengths of the PCR products representing them. For SLC39A14, no 
standard RT-PCR was performed. 
Gene Transcript variant Expression PCR product 
Short-exon-two High in tumour 266 bp SF1 
Long-exon-two High in normal 297 bp 
Short-exon-twelve High in tumour 222 bp DDX17 
Long-exon-twelve High in normal 603 bp 
Exon four High in tumour - SLC39A14 
Exon four primed High in normal - 
 
4.2.1 Splicing factor 1 (SF1) 
SF1, also known as branch point-binding protein (BBP), was considered a candidate 
gene in both studies; however, the most promising results were seen in the CRC 
study.  
SF1 is transcribed from the minus strand of cytogenetic band 11q13.1. The Ensembl 
Genome Browser, release 56, has annotated 21 transcript variants of SF1. 
The exon microarray data are shown in Figure 19A. The exon-wise plot implies that 
the overall expression of SF1 is quite similar in malignant and normal tissues from 
colon and rectum. However, three probe sets interrogating a known extension of exon 
two resulting from an alternative polyadenylation site event, indicate differential 
inclusion of sequence from this area immediately downstream of the constitutive part 
of exon two. A multiplex RT-PCR assay20 was designed (Figure 19B). In the first-
line validation this assay was performed on six of the same samples as examined by 
the exon microarray analysis, three of each of malignant and normal tissues from 
colon and rectum, which were manually selected based on the exon-wise plots. By 
this multiplex RT-PCR assay, the exon microarray results were reproduced and 
validated. 
                                               
20 Multiplex PCR – variant of PCR which enables simultaneous amplification of several targets of interest in one reaction 




Figure 19. SF1 (ENSG00000168066). (A) Expression levels of the different PSRs for SF1 
as seen from exon microarray data. The green and red lines represent the log-2 averages 
of the normal colon and CRC tissue samples, respectively. All exons are numbered 
according to ENST00000377390. APS (alternative polyadenylation site) represents an 
extension of exon two, and originates from an APS event. (B) The probe sets of interest, 
interrogating an intronic area close to exon two of the transcript used to name the exons 
(orange hatch), target the extension of exon two resulting from an alternative stop. Multiplex 
RT-PCR primers were designed to anneal to exons one, three and the extension of exon 
two as depicted. The reverse primer hybridising to the extension of exon two is coloured 
green, as it participates in the amplification of the transcript that seems to have a relatively 
higher level of expression in normal tissues, giving rise to a PCR product of 297 bp. The 
purple primers result in a PCR product of 266 bp. 
Subsequently, these transcripts were further investigated by performing the same RT-
PCR assay as used in the first-line validation on an extended sample series of clinical 
CRC and normal tissue samples, in addition to colon cancer cell lines. In short, the 
results show that the cancer tissue samples, in addition to the colon cancer cell lines, 
express a higher proportion of the transcript of the short-exon-two variant as 




Figure 20. RT-PCR and capillary electrophoresis of fluorescently labelled SF1 PCR 
products in a series of clinical CRC and normal tissue samples. The log-2 ratios 
between the amounts of short-exon-two (candidate cancer-specific variant) versus long-
exon-two RT-PCR products are shown for malignant and normal tissues from colon and 
rectum, in addition to colon cancer cell lines. Three of the cancer tissue samples did only 
give rise to the short-exon-two RT-PCR product peak in the capillary electrophoresis, and 
consequently these are not included in the boxplot. 
4.2.2 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 (DDX17) 
DDX17 is transcribed from the minus strand of cytogenetic band 22q13.1. The 
Ensembl Genome Browser, release 56, has annotated 16 transcript variants of 
DDX17. 
The exon microarray data are shown in Figure 21A. The exon-wise plot implies that a 
part of the intronic area between exons eleven and twelve (PSR mapping close to 
exon twelve in the genome), or possibly the whole intron (due to intron retention), 
has a higher level of inclusion in mRNA from normal tissue compared to CRC tissue. 
The first RT-PCR was performed with primers in exons eleven and twelve, but this 
yielded only one PCR product for every sample (size in accordance with expression 
of only exons eleven and twelve), which included six of the same samples as 
examined by the exon microarray analysis (three of each of malignant and normal 
tissues from colon and rectum). Based on this, a forward primer annealing to the 
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interesting area close to exon twelve was designed and run in multiplex with the 
former primer pair (Figure 21B), and for most samples two PCR products were 
synthesised. By this method, the exon microarray data were reproduced and 
validated. The interesting probe set was in a later release of the Ensembl genome 
browser found to target an extended exon twelve resulting from the use of an 
alternative promoter.  
 
Figure 21. DDX17 (ENSG00000100201). (A) Expression levels of the different PSRs for 
DDX17 as seen from exon microarray data. The green and red lines represent the log-2 
averages of the normal and CRC tissue samples, respectively. Exons are numbered 
according to ENST00000415456. (B) The probe set of interest, interrogating an intronic 
area close to exon twelve (orange hatch) was later found to target an alternative promoter 
(resulting in a long exon twelve). A multiplex RT-PCR assay was designed as depicted, 
resulting in two PCR products; the purple primer pair gives rise to a 222 bp PCR product, 
and primers internally in the long exon twelve give rise to a PCR product of 603 bp. 
Subsequently, these transcripts were further investigated by performing the same 
multiplex RT-PCR assay as used in the first-line validation on an extended sample 
series of clinical CRC and normal tissue samples, in addition to colon cancer cell 
lines (Figure 22). In short, the results show that the CRC tissue samples, and to a 
lesser extent the colon cancer cell lines, have a higher proportion of the transcript of 




Figure 22. RT-PCR and capillary electrophoresis of fluorescently labelled DDX17 PCR 
products in a series of clinical CRC and normal samples. The log-2 ratios between the 
amounts of short-exon-twelve (candidate cancer-specific variant) versus long-exon-twelve 
RT-PCR products are shown for malignant and normal tissues from colon and rectum, in 
addition to colon cancer cell lines. Thirty-eight of the 105 cancer tissue samples are not 
included in the boxplot, as 36 of them did only give rise to the short-exon-twelve RT-PCR 
product peak in the capillary electrophoresis, and two of them did not give rise to any peak. 
4.2.3 Solute carrier family 39 (zinc transporter), member 14 
(SLC39A14) 
SLC39A14, also known as Zrt- and Irt-like protein 14 (ZIP14), is transcribed from the 
plus strand of cytogenetic band 8p21.3. The Ensembl Genome Browser, release 56, 
has annotated four transcript variants of SLC39A14. 
The exon microarray data are shown in Figure 23A. From the exon-wise plot it seems 
that if exon four primed is expressed, exon four is not expressed, and vice versa, 
which implies that the two exons four are mutually exclusive. This assumption is 
reinforced by the fact that in known transcripts from this gene, the exons four-primed 
and four never exist in the same transcript. As the two exons four have identical 
lengths, it is impossible to differentiate between the two splicing events by standard 
RT-PCR with primers in flanking constitutive exons. Consequently, two real-time 
RT-PCR assays with exon specific probes were designed to validate the structure and 
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quantities of the transcripts resulting from these mutually exclusive splicing events 
(Figure 23B).  
 
Figure 23. SLC39A14 (ENSG00000104635). Expression levels of the different PSRs for 
SLC39A14 as seen from exon microarray data. The green and red lines represent the log-2 
averages of the normal and cancer tissue samples, respectively. Exons are numbered 
according to ENST00000289952; however, exon four-primed is not present in this 
transcript, but in another transcript of this gene. (B) Two known splicing events assumed to 
be responsible for the interesting exon-wise plot are depicted. The green and red lines 
represent the splicing events dominating in normal and cancer tissues, respectively. The 
two mutually exclusive exons four have identical size and similar sequences. Two real-time 
RT-PCR assays were designed with identical primers but distinct probes, as depicted. 
In the first-line validation, these assays were performed on 19 of the same samples as 
examined by the exon microarray analysis, three normals (which were selected based 
on the exon-wise plots) and 16 CRC tissue samples, in addition to six colon cancer 
cell lines (Figure 24). This method revealed a clear difference between normal tissues 
and CRC samples (both tissues and cell lines). The real-time assay with a probe in 
exon four primed detected accumulation of PCR product in all three normal samples 
(all samples are run in triplicates), but only in two of 16 tumour samples and in none 
of the six cell lines. Furthermore, the real-time assay with a probe in exon four 
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detected PCR product in all cell lines, in addition to 15 of 16 tumour samples, but in 
none of the normal tissue samples. 
 
Figure 24. First-line validation of SLC39A14 transcript variants by real-time RT-PCR. 
To the left, the real-time RT-PCR results (amplification plots) obtained with the assay 
containing the probe annealing to exon four-primed, which from the exon-wise plot seems to 
have a higher level of inclusion in normal tissue, are shown for all the samples included in 
the first-line validation; three normals, 16 CRC and six colon cancer cell lines. To the right, 
the corresponding data obtained with the probe hybridising to exon four are depicted. The 
fluorescence intensities (y-axis) are plotted against the number of PCR cycles (x-axis). The 
red horizontal line indicates the Cycle threshold (Ct). 
Subsequently, these transcripts were further investigated by expanding the sample 
series of clinical CRC and normal tissue samples. The Ct values obtained for each of 
these samples by the assay with a probe in exon four-primed were normalised against 
the Ct values obtained with a probe in exon four, and the results are shown in Figure 
25. Interestingly, the normal tissue samples consistently show negative relative 
expression values, and only two of 105 colorectal cancer tissue samples mix with the 
normal samples. Hence, setting a threshold at the highest value in the normal samples 
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yields a sensitivity of 98 % for this transcript variant. All the cell lines, and the great 
majority of the CRC tissue samples (97), show positive relative expression values. 
 
Figure 25. SLC39A14 real-time RT-PCR data in a series of clinical CRC and normal 
tissue samples, in addition to six colon sell lines, showing the relative expression 
between the two mutually exclusive splicing variants. The Ct values obtained in the 
assay with a probe in exon four-primed (“normal exon”) is normalised against the Ct values 
obtained in the assay with a probe in exon four (“cancer exon”), and this gives the relative 
expression along the y-axis (log-2) for each of the samples (x-axis). It is worth mentioning 
that all samples that did not cross the Ct line before cycle 34 were considered not to 
express the specific transcript, and were given the value 34 prior to the calculations. 
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5. Discussion 
In the present project, the aim has been to identify specific transcript variants, known 
or novel, but all of which have resulted from exon-level transcriptome analyses of 
CRC and TGCT. In the bigger picture, transcript variants that are specific to cancer 
cells, or to particular subgroups of cancers, have good potential as biomarkers or even 
as drug targets.  
The differential exon-level inclusion data destined for validation were generated 
using the Affymetrix Human Exon 1.0 ST Array, which contains probe sets 
interrogating more than one million annotated and predicted exons. With 
approximately four probes per exon, which means that for a gene containing ten 
exons there are roughly 40 probes matching its sequence, the gene-level estimates are 
generally in agreement with the true transcription level. However, the individual 
exon-level estimates are uncertain, leading to numerous false positive predictions of 
differential inclusion of sequence into mature RNA. Accordingly, it is decisive to 
investigate if the exon microarray data are reproducible by another method, e. g. RT-
PCR. Biologically validated transcript variants were further examined to determine if 
the candidates were interesting in an extended clinical sample series.  
Several of the candidate genes identified by exon microarrays and later passed 
validation in lab, have earlier been hypothesised to be implicated in cancer. 
Accordingly, it is not inconceivable that alternative splicing of these genes, or 
possibly alternative use of promoters and polyadenylation sites, might be functionally 
relevant in the development of cancer. Alternative RNA processing events may affect 
function by amongst others adding or deleting functional domains, changing affinities 
and altering mRNA stability. 
In this study, cancer-associated transcript variants have been identified. In the 
following, a more detailed discussion of the results and the methods is provided. 
Discussion 
 60
5.1 Transcript variation in testicular germ cell tumour 
Three alternative splicing events proposed by the exon microarray analysis 
comparing ES and EC cell lines were validated by RT-PCR. In all cases, the EC cell 
lines were found to have a relatively higher level of expression of a transcript missing 
a specific genomic area resulting from the use of an alternative 3’ splice site (PMF1), 
or skipping of one or two consecutive cassette exons (ZNF195 and DNMT3B, 
respectively). 
DNMT3B, which encodes a de novo DNA methyltransferase, and PMF1, which 
encodes a part of the MIS12 kinetochore complex [59], and in addition is involved in 
polyamine homeostasis [60], have both been shown to have links to the development 
of cancer. For instance, DNMT3B overexpression induced by HOXB3 results in 
promoter hypermethylation and silencing of the tumour suppressor gene RASSF1A 
[61], and in another study, PMF1 was identified to be epigenetically silenced in 
bladder cancer [62]. Polyamines are important regulators of proliferation and 
apoptosis [63], and defects in kinetochore formation may lead to aneuploidy and 
cancer; consequently, it is not inconceivable that PMF1 silencing may be functionally 
relevant in the development of cancer. ZNF195, which may be involved in 
transcriptional regulation, might also have a role in cancer. This zinc finger protein, 
first identified in the human T lymphoma cell line Hut78 [64], was found to be 
selectively expressed by cutaneous T-cell lymphoma cells, and a clone expressing 
part of ZNF195 was specifically recognized by sera of cutaneous T-cell lymphoma 
patients but not healthy donors [65]. Potentially, the alternative splicing of DNMT3B, 
PMF1 and ZNF195 could affect crucial protein domains and thus the activity and 
function of these proteins. 
Real-time RT-PCR, in addition to standard RT-PCR followed by capillary 
electrophoresis, revealed that DNMT3B expression was higher in ES and EC (both 
cell lines and tissues) compared to the other histological subtypes of TGCT, in 
addition to IGCN and normal tissue samples. These results agree with what was 
found in a study examining and comparing gene expression in all the histological 
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subtypes of TGCT, which among other things revealed that high DNMT3B 
expression was significantly associated with EC [66]. The qualitative transcript 
differences between ES, in addition to 2102Ep, and NTERA2 and NCCIT revealed 
by the exon microarray analysis and then validated by RT-PCR, may only show that 
the EC cell lines NTERA2 and NCCIT differ from the other EC, as 2102Ep and the 
EC tissue samples resemble ES. If this is in fact the case, differential splicing of 
DNMT3B is less interesting in a cancer stem cell context based on these results. 
Plotting of the real-time RT-PCR results against the transcript variant ratios for 
PMF1 clearly separated the samples (normal testicular parenchyma, IGCN, TGCT 
and ES cell lines) into two groups. However, as mentioned in the results, the groups 
were not separated by any obvious characteristics. Accordingly, although the exon 
microarray data were reproduced within ES versus EC cells, the transcript variants of 
this gene seems to be of less cancer-specificity in an extended sample series. 
Perhaps the most promising transcript variants identified in the TGCT study belong 
to the ZNF195 gene. This gene is highly expressed in both ES and EC (cell lines as 
well as tissue samples); however, there is a clear difference in the short (candidate 
cancer-specific) versus long transcript variant ratios between the two different 
groups. The TGCT subgroups are mostly separated with respect to distinct combined 
expression of the two transcript variants, and the gene expression is generally lower 
compared to ES and EC. Altogether ZNF195 is highly expressed in the pluripotency 
associated samples, and with a malignancy-specific expression pattern of the 
transcript variants. 
5.2 Transcript variation in colorectal carcinoma 
Three events resulting in differential expression of transcript variants proposed by the 
exon microarray analysis comparing malignant and normal tissues from colon and 
rectum were validated by other methods. By multiplex RT-PCR, normal tissues from 
colon were found to express a relatively higher level of transcript variants resulting 
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from the alternative use of a polyadenylation site (SF1) or promoter (DDX17) 
compared to malignant tissues and colon cancer cell lines. SF1 and DDX17 have both 
been shown to have links to the development of cancers.  SF1, which binds the BPS 
of pre-mRNA (see section 1.2.1), has been suggested to have a role in colon 
tumourigenesis by being a component of the TCF-4 and β-catenin21 complex and thus 
inhibiting the gene transactivational function of the complex [67]. DDX17, which 
encodes an RNA helicase amongst others involved in splicing, does also form a 
complex with β-catenin; however, the DDX17 protein (also known as p72) seems to 
promote the ability of β-catenin to activate gene transcription [68]. Potentially, the 
alternative use of a polyadenylation site (SF1) or a promoter (DDX17) could affect 
functional protein domains involved in gene regulation or changing the affinity for 
other transcription factors in the complex.  
Two real-time RT-PCR assays targeting each of the mutually exclusive SLC39A14 
exons reproduced the exon microarray data, and this gene appears to be the most 
promising biomarker candidate revealed in this study. SLC39A14 encodes a plasma 
membrane protein that functions as a zinc influx transporter [69]. Zinc is an essential 
cofactor for hundreds of enzymes [70], and this element is involved in the 
metabolism of macromolecules, as well as in the control of transcription, growth, 
development, and differentiation. The expression of one SLC39A14 splicing variant 
instead of the other could potentially affect zinc homeostasis, and accordingly several 
cellular processes, including those relevant in the development of cancer. As early as 
in 1950, Addink proposed a correlation between zinc and malignant growth [71], and 
a study examining hepatocellular carcinomas found that SLC39A14 is underexpressed 
in this form of cancer [72]. 
The two real-time RT-PCR assays detecting each of the SLC39A14 transcript variants 
resulting from differential inclusion of two mutually exclusive exons differentiated 
                                               
21 β-catenin is involved in the out-migration of enterocytes from the colonic crypt. Accumulated cytosolic β-catenin 
diffuses to the nucleus and associates with other transcription factors and regulates expression of growth-promoting genes 
and genes involved in differentiation. 
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well between normal and malignant tissues from colon and rectum. For most samples 
this was an “either or” situation; six of eight normal tissue samples did exclusively 
express the transcript variant with exon four-primed (“normal exon”), whereas 78 of 
105 (74 %) cancer tissue samples (and all the cell lines) did only express the exon-
four variant (“cancer variant”). Including the remaining samples, only two of the 105 
colorectal cancer tissue samples showed an expression ratio between the two different 
transcripts that mixed with the normal tissue samples. These real-time RT-PCR 
assays should be performed on an extended sample series including adenomas to 
determine if the shift in the expression of the transcript variants is an early event in 
the development of CRC. It is also worth mentioning that a standard curve for the 
real-time RT-PCR assay with a probe in exon four was produced by serially diluted 
UHR cDNA; however, this was not the case with the assay targeting the exon-four-
primed variant as this was not detectable within the UHR reference sample. 
Accordingly, SLC39A14 may have implication in other cancer types as well, as UHR 
cDNA contains cDNA from ten human cancer cell lines not including cell lines from 
colon and rectum. 
5.3 Methodological considerations – Assay design 
As mentioned in the description of RT-PCR primer design (section 3.3.2), validation 
of RNA processing events other than simple cassette exons and alternative 5’ and 3’ 
splice sites are often challenging. Some of these scenarios are discussed in the 
following. 
RT-PCR and subsequent capillary electrophoresis of fluorescently labelled PCR 
products do not discriminate between two mutually exclusive exons of exactly the 
same size (Figure 26A). This situation may seem unlikely, but was the case for the 
two exons four in SLC39A14, which in addition had almost identical sequences. This 
challenge was solved by aligning the two exon sequences of interest and designing 
sequence specific TaqMan MGB probes targeting an area of difference, and real-time 
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RT-PCR was carried out with the same pair of primers annealing to the constitutive 
exons flanking the two exons four (Figure 26B). 
  
Figure 26. Examining splicing events involving mutually exclusive exons of same 
size. (A) Primers in constitutive exons flanking the two mutually exclusive exons of same 
size, resulting in PCR products of identical lengths, which are not separated by capillary 
electrophoresis. (B) In this thesis, this problem was solved by performing a real-time RT-
PCR with sequence-specific probes targeting each of the two mutually exclusive exons four. 
Theoretically, it is possible to perform these PCR reactions in multiplex (the two different 
probes labelled by distinct dyes added in the same well); however, in this case only the 
single-plex setup (one probe in each well) worked. (C) In retrospect, it is evident that the 
two distinct transcripts could also have been distinguished by performing a multiplex PCR. 
(D) Additionally, the PCR products of different lengths in (A) could have been separated by 
capillary electrophoresis after treatment with a sequence specific endonuclease 
(represented by a “zig zag”) that cuts only one of the exons four. 
Prior to performing real-time RT-PCR, an alternative assay could have been 
considered (Figure 26C). Three primers could have been designed; one forward 
primer in each of the mutually exclusive exons, in addition to a reverse primer 
annealing to the downstream constitutive exon (or conversely, reverse primers in the 
mutually exclusive exons, and a forward primer in the constitutive upstream exon). 
The forward primers should have been placed in distinct relative positions within the 
two exons four, so that PCR products of separate lengths would have been 
synthesised representing the different transcript variants. This reasonable assay, with 
three primers in a multiplex PCR reaction, would have amplified the different 
transcript variants with distinct sets of primers, although the primer in the constitutive 
exon is mutual. For that reason, the PCR reaction efficiencies would have differed (e. 
g. due to distinct Tm optima of the two reactions). Hence, the true ratio between the 
different transcript variants could not have been deduced from the different amounts 
of amplified sequence from the two transcripts. Despite this inconvenience, this 
alternative assay could have been useful simply to examine if the gene was 
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interesting, as the amplification efficiency bias would have been the same for each 
sample. Therefore, if a difference between the two sample groups was observed, a 
follow-up real-time RT-PCR should have been performed. As the validation 
frequency of exon microarray data is rather low, it would normally not be profitable 
to perform a real-time RT-PCR on a candidate gene which has not passed a previous 
standard RT-PCR; however, in the case of SLC39A14, we were fortunate. 
Even in cases where the same set of primers amplifies the distinct transcript variants, 
the PCR reaction efficiencies can differ due to different amplicon lengths, as shorter 
fragments are more efficiently synthesised. Nevertheless, this produces less bias than 
the multiplex scenario previously described. 
A third option for distinguishing between transcripts with mutually exclusive exons 
of same size is to do a standard RT-PCR with primers in flanking constitutive exons, 
and then, prior to capillary electrophoresis, the PCR products can be cleaved by a 
restriction enzyme specific to one of the sequences (Figure 26D). However, in our 
example gene, finding a variant specific restriction enzyme is difficult due to the high 
degree of sequence homology between the two mutually exclusive exons. 
Validation of alternative use of promoters and polyadenylation sites requires 
placement of a primer within the exon of interest because the target exon does not 
connect to flanking exons on both sides. In these cases, two separate PCR reactions 
should be performed; one that determines the presence or absence of the exon of 
interest, and another that measures the alternative pattern or the expression level of 
the gene. Accordingly, multiplex PCR reactions were carried out for DDX17 and 
SF1, which represent alternative start and stop events, respectively. However, crucial 
DDX17 and SF1 transcript variants were not known at the time of the first primer 
design. Consequently, the initial primer pairs were designed to anneal to exons 
flanking the area of interest, and in each case these incomplete assays yielded only 




Figure 27. Validation of differential use of promoters and polyadenylation sites. In 
cases with alternative starts (here represented by DDX17) or stops (represented by SF1), a 
straight-forward strategy with a pair of primers in exons flanking the area of interest (orange 
hatch in Ensemble release 53 transcripts), as depicted in the RT-PCR assays in both (A) 
and (B), leads to the synthesis of only one PCR product. These simple RT-PCR assays 
were designed due to ignorance of existing, but still unknown, transcript variants. The 
interesting probe sets in DDX17 (targeting an area close to exon twelve) and SF1 (close to 
exon two) targeted introns in the Ensembl release 53 transcripts, which aroused suspicion 
about unknown alternative 3’ or 5’ splice site events, respectively, or possibly intron 
retention. (A) As the straight-forward RT-PCR assay yielded only one product, a forward 
primer targeting the area of still unknown nature, appearing from the exon-wise plot to have 
a higher level of inclusion in normal tissue as compared to CRC tissue, was designed and 
run in multiplex with the primer pair constituting the previous RT-PCR assay. The ratio 
between the two synthesised PCR products differed between normal and CRC. 
Subsequently, Ensembl release 56 displayed an alternative promoter (AP) in the interesting 
area of DDX17. (B) An interesting transcript from the database of the University of California 
Santa Cruz (UCSC)22 with an extended exon two resulting from alternative polyadenylation 
site (APS) usage was overlooked, and the RT-PCR assay design was accordingly solely 
based on known transcript variants in Ensemble release 53 and the exon-wise plot, and this 
assay yielded only one PCR product. Subsequently, when the nature of the interesting area 
was noticed, a multiplex RT-PCR assay with one primer in each of the exons one, three and 
the extension of exon two was designed as depicted. Later, one more interesting transcript 
containing the extended exon two was found in Ensembl release 56. This transcript did not 
express the part of exon one targeted by the forward multiplex primer. Consequently, if this 
transcript also contributes to the divergent exon-wise profile, the performed assay is 
incomplete. This may be the case in the TGCT study, as this gene was a candidate in both 
studies, but it was only validated in the CRC study. 
These scenarios illustrate the importance of manual inspection and visualisation of 
the exon microarray data in a genomic context prior to designing assays for 




validation, as exon microarrays do not reveal which exons are actually physically 
linked. However, incomplete collections of transcript variants in the genome 
browsers may lead to the design of assays not including all the transcripts responsible 
for creating the divergent exon-wise plots. During the master project, the number of 
known transcript variants in the public data bases has virtually exploded, reflecting 
the true complexity of biology. For instance, Ensembl release 52 (December 2008) 
has two transcript variants annotated for the ING4 gene, whereas Ensembl release 56 
(September 2009) alleges that ING4 has a total of 23 transcripts. Additionally, several 
transcript variants have been withdrawn. GCNT3 represents a frightful instance of 
this; both Ensembl release 53 and 56 revealed two GCNT3 transcripts, apparently the 
same, as the transcript numbers were matching; however, the ENST00000267857 
transcript contains different exons in the different Ensembl releases. If the last 
Ensembl release represents the true biology of this gene, the RT-PCR validation 
assay, which was based on Ensembl release 53, is deficient. However, with such 
wide-spread changes in the annotation during a 10-month period, it is likely that the 
current information in the Ensembl database is still quite far from the real-life 
situation. Thus, detailed transcript validation analyses of genes and probesets 
resulting from exon microarray analyses would have been warranted even if the 
technology itself were producing perfect data. Data generated from deep sequencing 
of cDNA fragments have barely started to accumulate; hence, it is expected that the 
complexity of the known transcriptome will dramatically increase. 
Finally, it should be noted that if an intron retention event was expected of a large 
intron, the elongation time in the RT-PCR thermal cycling was increased. 
Subsequently, the RT-PCR products were analysed by capillary electrophoresis as 
well as on an agarose gel, as the former detection method is somewhat difficult to 
perform on larger fragments. 
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5.4 Methodological considerations – Detection of PCR 
products 
To differentiate between inclusion and skipping events on an agarose gel, the overall 
size of the amplicon should be designed relative to the size of the interesting area. 
The smaller the interesting area, the smaller the amplicon sizes should be to clearly 
separate the skip/include products on a gel. In some cases it was difficult to design 
assays yielding PCR products that could be resolved on an agarose gel, and in other 
cases, the differences in band densities were not easily evaluated. Therefore, several 
of the genes were analysed by capillary electrophoresis and detection of fluorescently 
labelled PCR products. During the course of the project, it was decided to apply this 
method as the default strategy, even if a gel-based assay could have given the desired 
results. The capillary electrophoresis enabled improved resolution of PCR products of 
approximately the same size (generally down to one nucleotide in size difference). In 
addition, this fluorescence-based method is much more sensitive and also produces 
fairly quantitative results, thus enabling semi-quantitative measures of the ratio 
between different transcript variants. One reason for being more quantitative is that 
the high sensitivity allows termination of the PCR reaction at an earlier cycle and thus 
measurements of accumulated product in a phase more representative of the transcript 
input amount. However, real-time RT-PCR, which reveals the amplification plot, is 
the superior method when more accurate quantitative measurements are required. 
Theoretically, there is a quantitative relationship between the amount of starting 
template and the amount of PCR product at any given cycle. In real-time PCR, the 
quantity of PCR product is measured after each cycle, as opposed to traditional PCR, 
where the accumulated target sequence is analysed only after a fixed number of 
cycles. 
In this thesis, sequence specific TaqMan MGB probes were utilized in the real-time 
RT-PCR experiments, and consequently only the synthesis of target DNA is 
measured. This method is costly and challenging compared to standard PCR, and was 
therefore reserved promising candidates, most of which had passed a previous 
standard RT-PCR. However, in most situations it was difficult to design a real-time 
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assay targeting both transcript events, and hence the real-time RT-PCR was 
performed to determine the quantity of one of the transcripts, and standard RT-PCR 
followed by capillary electrophoresis were carried out to obtain the ratio between the 
amounts of the different transcript variants. Multiplexing of two real-time RT-PCR 
reactions, which involve amplification of both transcript variants with the same set of 
primers, and detection of the different transcripts by distinct probes (labelled with 
different reporter dyes, e. g. FAM and VIC) added in the same well, would provide 
the most accurate estimate on the ratio between the amounts of the different transcript 
variants. However, the attempt to do this for the SLC39A14 gene was unsuccessful, 
perhaps due to oligo dimerisation. Additionally, multiplex RT-PCR was planned for 
the DNMT3B gene, yet this was impossible as the long PCR product (295 bp) was not 
amplified by the TaqMan thermal cycling (the real-time RT-PCR product was 
analysed on an agarose gel), neither in single-plex nor multi-plex, maybe owing to a 
too short elongation time. Nevertheless, Applied Biosystems informs that the enzyme 
can synthesise 2-4 Kb/min, and consequently this should not be a problem, as the 
combined annealing and elongation time was one minute. 
5.5 Validation frequency 
For the candidate genes tested in the lab, the validation rate in the CRC and TGCT 
studies were 43 % (3 out of 7) and 13 % (3 out of 24), respectively, whereas the total 
validation frequency was 20 % (6 out of 30; SF1 was a candidate gene in both 
studies, but only validated in the CRC series).  
The validation rate in the CRC study was quite good compared to other studies 
qualitatively examining colon cancer transcriptomes, which confirmed 26 % [73] and 
approximately one-third [35] of the differential splicing events proposed by exon 
microarrays. The overall validation rate in this thesis was reduced by the candidates 
resulting from the exon microarrays comparing ES and EC cells. This is probably due 
to the fact that these two sample types are very similar in most respects, including at 
the transcriptome level. Consequently, the candidate event p-values destined for 
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examination in the lab in the CRC study were in general lower than in the TGCT 
study. Furthermore, the FIRMA algorithm (section 3.2) was only utilised in the CRC 
study. The use of this algorithm, followed by manual examination of the exon-wise 
plots, may have revealed a greater proportion of the false positives than by manual 
examination alone, which was the case in the TGCT study. 
The design of an incomplete RT-PCR assay not including all the transcript variants 
responsible for the divergent exon-wise profile, may lead to rejection of a true 
positive candidate gene, which accordingly is wrongly categorised as a false positive 
(discussed in section 5.3). However, numerous actual false positives are generated by 
the exon microarrays and contribute considerably to the rather low validation 
frequency. In the following, scenarios that might result in such artificial predictions 
of qualitative transcriptome differences will be discussed. 
As mentioned in section 1.2.3 (Global analysis of transcript variation), DNA 
microarrays have traditionally interrogated only the 3’ ends of RNAs. For oligo DNA 
microarray providers other than Affymetrix, generally one individual probe, typically 
of about 60 nucleotides in length, is used per gene. The Affymetrix arrays use 25mer 
oligo probes, and the 3’ biased microarrays from this vendor has used a collection of 
11 probes, constituting a probe set, for each measurement. For the Affymetrix exon 
microarrays, there are individual probe sets targeting each individual exon, but each 
probe set is here reduced to include four probes, which again results in less reliable 
values for the individual probe sets, and hence a greater portion of false positives. 
Furthermore, using exon-level detection instead of gene-level detection forces the 
issue of multiple comparisons, where the larger the number of exons in the gene, the 
greater the chance of high statistical significance by chance alone. This problem 
should be corrected for by the use of Benjamini and Hochberg FDR; however, 
several false positives arising from multiple comparisons will not be filtered out. 
The generation of background noise in the exon microarray data, e. g. due to low 
sample quality, may also contribute to false positives. This is of great importance to 
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candidates that have large gene expression differences between the two groups, as a 
large disparity in transcription rate makes it more likely that probe set intensities in 
the two groups are disproportionately affected by the noise. 
The expression level of a given exon is a result of the transcription rate of the entire 
gene and the inclusion rate of that exon. Therefore, to reveal differential inclusion of 
a specific PSR in mature RNA, it is crucial to normalise the probe set intensity to the 
expression level of the gene harbouring the interesting PSR. Consequently, the 
combination of a misleading probe set result and differential gene expression may 
create a false prediction of alternative splicing, or alternative start or stop (Figure 28). 
However, the majority of these false positives are filtered out automatically in the 
analysis of the exon microarray data, and most of the remaining cases can be revealed 
manually by inspecting the exon-wise plots. 
 
Figure 28. Scenarios that may lead to divergent transcript profiles and consequently 
false predictions of alternative splicing events. In each case, it is the combination of a 
misleading probe set result and differential gene expression that creates a false prediction 
of alternative splicing. (A) A cross-hybridising probe set giving rise to a high signal 
regardless of the actual expression of the interrogated PSR is depicted. Consequently, this 
PSR will appear to have a greater inclusion in the sample group that has a lower expression 
of the cognate gene. All interesting probe sets were visualised and inspected in the X:Map 
Genome Browser, which gave warnings when searching for probe sets known to be cross-
hybridising. Such candidate events were not included in the validation pipeline. (B) and (C) 
A dysfunctional probe set may produce a false evidence for differential splicing in cases 
where the gene is expressed in only one of the sample groups and in cases with differential 
gene expression, respectively. Consequently, candidate genes that are not expressed in 
both sample groups, in addition to PSRs not expressed in at least one sample group, 
should be filtered out. 
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Candidate genes consistent with known alternative splicing, or alternative start or 
stop events, are more likely to be true positives. Nevertheless, in this thesis, candidate 
events representing possible unknown transcriptome diversifying events were not 
excluded, as this would have made the discovery of novel transcripts impossible. 
However, none of these candidates were validated, and hence these hypothetical 
events lowered the validation frequency. 
Generally, the predicted splicing events that remain after different types of filtering 
are more likely to be true positives. However, it should be noted that filtering the data 
in an attempt to reduce the amount of false positives generally also involves loss of 
true positives. 
In general, it was found that the smaller the p-value, and the greater the magnitude of 




During this study, we have established a pipeline for experimental validation of 
transcript variations detected by high resolution exon-level transcriptome analyses. 
We have shown that in total about 20 % of such variation can be validated although 
this may vary between test series. A transcript variant of ZNF195 is shown to be 
promising as a cancer specific marker in a stem cell context. Furthermore, a transcript 
variant of the SLC39A14 is shown to be a promising novel biomarker for CRC with 
98 % sensitivity as compared to normal mucosa samples. 
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7. Future studies 
To elucidate the potential clinical applicability of the presented candidate cancer-
specific transcripts, we need to examine these in larger clinical series, including more 
normal colorectal cancer tissue samples. Furthermore, especially in the case of 
SLC39A14 alternative splicing variants, we would like to test a series of adenomas to 
explore whether a potential diagnostic test could be sensitive to precursor lesions. 
The novel biomarkers could be tested for in various biological specimens, e. g. faeces 
and blood. Preferably, a test at the protein level would be sought. In most of our 
successfully validated transcripts, as is the case for ZNF195, a section of the 
transcript is lacking in the cancer samples as compared to the corresponding normal 
samples. Thus, commercially available antibodies are unlikely to target the cancer 
specific exon-exon junction epitope. A possibility would be to custom-order 
antibodies targeting this region, and apply these immunohistochemically to tissue 
microarrays of colorectal carcinomas and TGCTs already constructed in our 
department. 
Biomarker applications do not necessarily require functional insights on the specific 
variants. However, identified cancer-specific transcripts may as well shed light on 
biological processes connected to cancer development, and not at least, they may 
serve as potential drug targets. The functional consequences of cancer-specific 
transcript variants will be examined by performing RNA interference based on short 
interfering RNAs (siRNA) or short hairpin RNA in cell lines with identified 
expression of the particular variant. These small RNAs can silence the expression of 
specific transcript variants by either post-transcriptional silencing or transcriptional 
silencing [74]. Recently, it has been shown that siRNAs targeting intronic or exonic 
sequences close to an alternative exon can regulate the splicing of that exon by local 
heterochromatin formation and consequently a slow-down in RNA polymerase II 
elongation, which may result in exon inclusion (recall from section 1.2.1) [75]. 
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In the present thesis, transcript variants from four genes have been introduced as 
potential cancer biomarkers. As relatively few of the CRC study candidate genes 
were examined in the lab, and the proportion of validated genes was quite high, it 
may be advantageous to add more of these candidates into the validation pipeline. 
Furthermore, in our group, exon microarrays are now performed on more samples of 
both CRC tissue samples and EC and ES cell lines, and subsequent analysis of these 
data will certainly propose more candidates worthy further examination. 
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Appendix I – Primer and probe information 
Modification 
Gene Probe set(s) Name Type Sequence 5' 3' Study 
ABCC3 3726746 ABCC3_ex24_F_6FAM f GTGGATGCCAACCAGAGAAG 6-FAM  CRC 
ABCC3 3726746 ABCC3_ex29_R r CTCTGAGTAGCTGCCGAAGG   CRC 
ABCC3 3726746 ABCC3_ex24_F_TM F GAGAAGCTGCTACCCCTACATCA   CRC 
ABCC3 3726746 ABCC3_ex25_R_TM R ACGAACTCCACTCCGATGCT   CRC 
ABCC3 3726746 ABCC3_ex24/25_P P CTCCAACCGGTGGCT 6-FAM MGB, NFQ CRC 
ARSB 2863982 ARSB_ex7_F f GCTCCAGCAAAGGATGACTC   TGCT 
ARSB 2863982 ARSB_ex8_R r AGCCACAGTCATGGTGCAG   TGCT 
ASPH 3137569, 3137566 ASPH_ex16_F_6FAM f CGCAAATACCCTCAGAGTCC 6-FAM  CRC 
ASPH 3137569, 3137566 ASPH_ex19_R r GCCTTCAGGATGAAGCCATA   CRC 
ASPH 3137569, 3137566 ASPH_ex20_R_6FAM r TCTTTGTTCCCAACCCTCTG 6-FAM  CRC 
ASPH 3137569, 3137566 ASPH_ex17/18_F f TTTCTAGGTCATATGAGAGGTTCC   CRC 
ASPH 3137569, 3137566 ASPH_ex10_F f AACATACCAAGTCTATGAGGAACAA   CRC 
ASPH 3137569, 3137566 ASPH_ex9_F f AAGATGAAAGATTGCACCATGA   CRC 
ASPH 3137569, 3137566 Hs00944865_m1 a Unknown 6-FAM MGB, NFQ CRC 
C2orf33 2530554 C2orf33_ex3_F_6FAM f TGCTAGTGTGATAATGCAAGTTCC 6-FAM  TGCT 
C2orf33 2530554 C2orf33_ex5_R r GACCGCTCTCTTTTTAGTCTGC   TGCT 
CTNNB1 2618981 CTNNB1_ex15_F_6FAM f CTCCAGGTGACAGCAATCAG 6-FAM  TGCT 
CTNNB1 2618981 CTNNB1_ex16_R r CAAGCAAGGCTAGGGTTTGA   TGCT 
DDX17 3960648 DDX17_ex11_F_6FAM f GGCACCCATCCTTATTGCTA 6-FAM  CRC 
DDX17 3960648 DDX17_ex12_R r GCCTCTTCCAGCACTTTGAT   CRC 
DDX17 3960648 DDX17_int11-12_F_6FAM f CAGGCTTCTCCCAACAGAGT 6-FAM  CRC 
DNMT3B 3882060, 3882062 DNMT3B_ex19_F fs TACTTCTGGGGCAACCTACC   TGCT 
DNMT3B 3882060, 3882062 DNMT3B_ex19_F_6FAM f TACTTCTGGGGCAACCTACC 6-FAM  TGCT 
DNMT3B 3882060, 3882062 DNMT3B_ex22_R rs ATGCCTTCAGGAATCACACC   TGCT 
DNMT3B 3882060, 3882062 DNMT3B_ex19_F_TM F GATGCCATCAAAGTTTCTGCTG   TGCT 
DNMT3B 3882060, 3882062 DNMT3B_ex22_R_TM R TGGACACGTCTGTGTAGTGCAC   TGCT 
DNMT3B 3882060, 3882062 DNMT3B_ex19/22_P P ATGAACAGGATCTTTG VIC MGB, NFQ TGCT 
DNMT3B 3882060, 3882062 DNMT3B_ex20/21_P P TAGCCAAGTTAAAGAAAG 6-FAM MGB, NFQ TGCT 
EXOSC8 3485880 EXOSC8_ex4_F_6FAM f TCTGCTTTAGTGAAGTTGGGAAA 6-FAM  TGCT 
EXOSC8 3485880 EXOSC8_ex8_R r CATCGTAGTCGAGGCAAATG   TGCT 
GCNT3 3596161 GCNT3_ex1_F_6FAM f TGCTGAAGGGAAACAGATGA 6-FAM  CRC 
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GCNT3 3596161 GCNT3_ex2_R r AGGAACAGTTTCAGGCTCCTC   CRC 
HLTF 2700225 HLTF_ex7_F_6FAM f TTTCTGAGAAGGACCGACCA 6-FAM  TGCT 
HLTF 2700225 HLTF_ex9_R r TCCATCTGCCTTTTCACTGG   TGCT 
HSD17B4 2825746 HSD17B4_ex4_F f TTGTGAAGACAGCCCTGGAT   TGCT 
HSD17B4 2825746 HSD17B4_ex7_R r CGTGTCACTTGGAATGAACC   TGCT 
ING4 3442194 ING4_ex1_F f GGATCGGAAGTTGCTTTGTT   TGCT 
ING4 3442194 ING4_ex4_R r CTTTTTGCCTTTGCTGGAAG   TGCT 
ITGA5 3456736 ITGA5_ex27_F f AGTTGCATTTCCGAGTCTGG   TGCT 
ITGA5 3456736 ITGA5_ex29_R r CATAGCTGCCTTCTGCCTTG   TGCT 
JUN 2415098 JUN_ex1_F_6FAM f CCACGCAAGAGAAGAAGGAC 6-FAM  TGCT 
JUN 2415098 JUN_ex1_R r AGGGAGCGCAGGGTTAAT   TGCT 
NANOG 3403437 NANOG_ex1_F f TCCTTGCAAATGTCTTCTGCT   TGCT 
NANOG 3403437 NANOG_ex3_R r TGCGTCACACCATTGCTATT   TGCT 
NR4A1 3415268 NR4A1_ex7_F f CACAGCTTGCTTGTCGATGT   TGCT 
NR4A1 3415268 NR4A1_ex8_R r ATGGGGTGGCATATGAGAGT   TGCT 
PBRM1 2676224 PBRM1_ex25_F_6FAM f GTGGGGACAGAATGGAGAAA 6-FAM  TGCT 
PBRM1 2676224 PBRM1_ex29_R r ATATGGAGGTGGTGCCTGCT   TGCT 
PMF1 2361418 BGLAP_ex3_F_6FAM f AGCTGTCTTGAATGCCTTGG 6-FAM  TGCT 
PMF1 2361418 BGLAP_ex4_R r GTTCTCGGCCTCCTGTTTCT   TGCT 
PMF1 2361418 BGLAP_ex3_F_TM F AAGAAGGCAAAGTCCGCAAA   TGCT 
PMF1 2361418 BGLAP_ex4_R_TM R GGCCTCCTGTTTCTGCACAT   TGCT 
PMF1 2361418 BGLAP_ex3/4_P P AGCCTGCAACGGGA 6-FAM MGB, NFQ TGCT 
PTPRU 2327826 PTPRU_ex3_F(2) f ATCCTGCTTCTCAGCTACCC   TGCT 
PTPRU 2327826 PTPRU_ex7_R r ACGTTGTAGCCCAGTGGTTC   TGCT 
SF1 3377080, 3377078, 3377077 SF1_ex2_F_6FAM f CCCAAGTAAGAAGCGGAAGA 6-FAM  Both 
SF1 3377080, 3377078, 3377077 SF1_ex1_F_6FAM f GAGGCTTGCGAAGGAGAAG 6-FAM  Both 
SF1 3377080, 3377078, 3377077 SF1_ex3_R r GTGCGCAGTTTACGAGTCAG   Both 
SF1 3377080, 3377078, 3377077 SF1_ex2’_R(2) r AAAATGCAGATCTTGCTCAGAA   Both 
SLC39A14 3089375, 3089381, 3089382 SLC39A14_ex3_F_TM F GGCCAAGCGCTGTTGAAG   CRC 
SLC39A14 3089375, 3089381, 3089382 SLC39A14_ex5_R_TM R TCTTCCAGAGGGTTGAAACCAA   CRC 
SLC39A14 3089375, 3089381, 3089382 SLC39A14_ex4’_P P CTCACTGATTAACCTGGCC 6-FAM MGB, NFQ CRC 
SLC39A14 3089375, 3089381, 3089382 SLC39A14_ex4_P P ACCGTCATCTCCCTCTG VIC MGB, NFQ CRC 
SLC6A6 2611941 SLC6A6_ex12_F_6FAM f TTGTGGGTTGCATTCTTTGA 6-FAM  CRC 
SLC6A6 2611941 SLC6A6_ex14_R r TTGACGAGCGAGAAGATGAA   CRC 
SMARCAD1 2736280 SMARCAD1_ex5_F_6FAM f CAAGCACTATGGATGGAGCA 6-FAM  TGCT 
SMARCAD1 2736280 SMARCAD1_ex9_R r CCATTTGGAACCTCACTTTG   TGCT 
SNRPN 3584495 SNRPN_ex3_F_6FAM f TGGAGTAGCGAGGAATCTGA 6-FAM  TGCT 
SNRPN 3584495 SNRPN_ex5_R r CATCTTGCAGGATACATCTCATT   TGCT 
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SPAG9 3762591 SPAG9_ex2_F_TM F GCGAAAAACTATGCTGACCAGA   TGCT 
SPAG9 3762591 SPAG9_ex3’_F_TM F GTGGCAGCAAGCTGAATGAC   TGCT 
SPAG9 3762591 SPAG9_ex5_R_TM R TCTCCAGCAGGTAATGGGAAA   TGCT 
SPAG9 3762591 SPAG9_ex3/4_P P CACACTGAGATGATCCAT VIC MGB, NFQ TGCT 
SPAG9 3762591 SPAG9_ex3’_P P CTGCTGTTTGTGTTTGG 6-FAM MGB, NFQ TGCT 
TARBP2 3416118 TARBP2_ex1_F f CTCGTCGGCTGTGTATTGG   TGCT 
TARBP2 3416118 TARBP2_ex2_R r CAGGCGTCTTCCCTATTCTG   TGCT 
TDGF1 2620943 TDGF1_ex1_F f CGATGCTAACGCCTCTTTTC   TGCT 
TDGF1 2620943 TDGF1_ex3_R r GAGATGGACGAGCAAATTCC   TGCT 
UBA6 2771755 UBA6_ex20_F_6FAM f TGAAGTTATTGTACCGCATTTGA 6-FAM  TGCT 
UBA6 2771755 UBA6_ex23_R r CAGCCTTCTAAACTGTGTCCA   TGCT 
UCK1 3227651 UCK1_ex4_F_6FAM f GTTTGAGGGCATCTTGGTGT 6-FAM  TGCT 
UCK1 3227651 UCK1_ex7_R r TCAGAATGTCCTGGATGTGC   TGCT 
ZNF195 3359764 ZNF195_ex4_F f TGGGATTTCACCATGCTACTC   TGCT 
ZNF195 3359764 ZNF195_ex4_F_6FAM f TGGGATTTCACCATGCTACTC 6-FAM  TGCT 
ZNF195 3359764 ZNF195_ex6_R r CTGGCAGAAGGTCTTGGGTA     TGCT 
Abbreviations: f, forward RT-PCR primer; r, reverse RT-PCR primer; F, forward real-time RT-PCR primer; R, reverse real-time RT-PCR primer; P, TaqMan 
MGB probe; a, TaqMan gene expression assay (contains both primers and probe); fs, forward RT-PCR and sequencing primer; rs, reverse RT-PCR and 
sequencing primer. 
